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MYC oncoproteins 
 
 
Myc Family 
 
In 1979 a viral oncogene directly involved in transformation induced by Rous Sarcoma Virus 
(RSV) was discovered, some years later the human homologue was discovered: c-Myc[1]. 
This new human oncogene was hardly investigated and after few years other two genes 
homologous to c-Myc was discovered: N-Myc[2] and L-Myc[3]. So three genes characterized 
by a good degree of homology compose the Myc family. 
It has been known for some time that c-Myc, N-Myc and L-Myc are expressed in distinct 
patterns during embryogenesis [4];[5]. c-Myc tends to be highly expressed in most rapidly 
proliferating cells and is generally low to absent during quiescence. N-Myc, although present 
at low levels in many neonatal tissues, is expressed at highest levels in pre-B cells, kidney, 
forebrain, hindbrain and intestine. In some tissues such as the retina, telencephalon, and 
intestine, MYCN expression has been shown to persist during differentiation whereas c-Myc 
is downregulated.[6, 7] 
During gastrulation, c-Myc is expressed most abundantly in extraembryonic tissues, whereas 
MYCN is most abundant in the expanding primitive streak and other regions of the embryonic 
mesoderm. N-Myc is also down-regulated during the differentiation of this latter tissue to 
epithelium[8]. L-Myc is expressed in the developing kidney, as well as in the newborn lung 
and in both proliferative and differentiative compartments of the brain and neural tube [9]. 
The Myc oncoproteins are transcription factors belonging to a subset of the larger class of 
proteins containing basic-region/helix–loop–helix/leucin-zipper (BR/HLH/LZ) motifs. 
BR/HLH/LZ domain is known to mediate protein-protein interactions and DNA binding [10]. 
They are structurally very similar as shown in Fig.1. 
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Figure 1. Structural domains of Myc oncoproteins. From N-term to C-term: 
Transactivation domain, TAD (amino acids (aa) 1–143): the TAD can confer activation of gene transcription to a 
heterologous DNA-binding domain. 
MYC homology box I, MB I (aa 44–63): MBs are regions highly conserved between MYC, N-MYC and 
MYCL1; within MB I, stability and activity of MYC are highly regulated through phosphorylation of Thr58 and 
Ser62. 
MB II (aa 128–143): this domain is important for transcriptional repression and activation, region of interaction 
with TRRAP and other cofactors involved in transformation. 
MB IIIa (aa 188–199): this domain is conserved in MYC and N-MYC but not in MYCL1 and shows 
intermediate transforming potential compared with the activity of the wild type MBII in vivo. 
MB IIIb (aa 259–270): this domain is conserved, but no specific function has yet been assigned to it. 
MB IV (aa 304–324): this domain is required for full MYC transforming activity and apoptosis. 
Primary nuclear localization signal, NLS (aa 320–328): subcellular localization to the nucleus is encoded 
primarily by this region. 
Basic region, BR (aa 355–369): this region is essential for full transformation of primary and immortal cells, and 
is responsible for specific binding of canonical and non-canonical MYC E-boxes to DNA, with MAX. 
Helix–loop–helix–leucine zipper, HLH–LZ (aa 370–439): this domain is essential for full transformation of 
primary and immortal cells, and is responsible for interaction with MAX [11]. 
 
 
The Myc/Mad/Max network and the transcriptional control of cell behavior 
 
The Myc/Mad/Max network comprises a group of nuclear transcription factors whose 
functions profoundly affect cell behavior [10]. 
No monomeric Myc proteins have been found in vivo. Instead, Myc is bound to a partner 
protein, Max (MYC-associated factor-X), itself a small BR/HLH/LZ protein [12]. Max, 
physiologically, is present in stoichiometric excess to Myc, and can homodimerize and bind 
DNA, but such Max homodimers appear to be transcriptionally inert [13, 14]. Max can also 
form heterodimers with several related proteins, known as Mad1, Mxi1 (also known as 
Mad2), Mad3, Mad4 and Mnt (also known as Rox) (Figure 2). These five proteins, that 
compose the Mad protein family, behave much like Myc in that they have only weak 
homodimerization and DNA-binding capacities but readily heterodimerize with Max and bind 
the DNA [10]. 
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Figure 2. Max-interacting proteins. Max forms heterodimers with members of the Myc and Mad protein families 
as well as with the Mnt (or Rox) and Mga proteins. Each of these proteins interacts with Max through its 
BR/HLH/LZ domain [15]. 
 
Association of Myc with Max results in the formation of heterocomplexes that recognize the 
hexameric DNA sequence CACGTG (belonging to the larger class of sequences known as E-
boxes, CANNTG) with transcriptional activity (Figure 3) [16-18]. However, in contrast to 
Myc, which activates transcription at promoters proximal to E-box sites, the Mad-Max 
heterodimers act as transcriptional repressors at the same binding sites [13] [19] [20]. 
 
 
 
 
Introduction 
4 
Figure 3. A, Structure of heterodimer Myc-Max bound to DNA; B, Structure of heterodimer Mad-Max bound to 
DNA. 
 
The ability to modulate transcription is derived from specific domains within the Max 
interacting factors which, in turn, appear to mediate associations with specific coactivators or 
corepressors, resulting in the formation of higher-order complexes. Furthermore, the different 
complexes may have antagonistic properties whose functions play out at the level of 
chromatin structure (see below). The transcription activation function of Myc involves at least 
in part the recruitment of a histone acetyltransferase (HAT) mediated by TRRAP 
(transactivation/transformation- associated protein), whereas Mad–Max complexes act as 
transcriptional repressor by recruiting histone deacetylases (HDACs) through the adaptor 
protein SIN3 (Figure 4) [21] [22]. 
In general, Max interacting proteins have short half-lives (on the order of 20–30 min) and 
their biosynthesis is highly regulated [23]. Max, on the other hand, is stable and constitutively 
expressed, suggesting that the regulation of the network is largely dependent on the 
abundance of the Max associated transcription factors that must be tightly regulated [12, 24]. 
In vivo, Myc–Max complexes are often predominant in proliferating cells, whereas Mad–Max 
or Mnt–Max complexes are predominant in resting or differentiated cells (see below) [25]. 
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Figure 4. Transcriptional regulation by Myc/Mad/Max network through E-box elements [21]. 
 
Our understanding of the Myc/Max/Mad network grew out of research on the MYC oncogene 
family. The first compelling idea about MYC was that its function was to drive cell growth 
and proliferation in response to diverse signals. In fact, MYC family genes are broadly 
expressed during embryogenesis, and targeted deletions of c-MYC or N-MYC genes in mice 
lead to lethality in mid-gestation embryos [26] [27]. Moreover, there is a strong correlation 
between MYC expression and proliferation. [9, 28-33]. In cells with activated MYC, G1 
phase is often shortened as cells enter the cell cycle, and MYC is essential for G0/G1 to S 
phase progression [34] [35] [36]. 
It is now clear that a wide range of growth factors, cytokines, and mitogens induced MYC 
expression in many cell types by [37-39].The increase in MYC levels occurs through both 
transcriptional and post-transcriptional mechanisms and appears to occur as an immediate 
early response (about 2 hours) to most mitogenic factors [40]. 
On the contrary, anti-proliferative signals trigger rapid downregulation in MYC expression 
[11]. MYC downregulation is required for cells to exit the cell cycle and undergo 
differentiation. This important point of regulation is further enforced by the induction and 
function of the Mad family members in response to differentiation cues [41]. 
It is important to note, however, that in situations where commitment to a specific lineage is 
closely linked to an increase in proliferation, Myc can promote differentiation [42]. 
Clearly, these data indicated that MYC is a nexus for multiple growth signal response 
pathways. Therefore MYC expression, and MYC activity, is tightly regulated in non-
transformed cells and designed to respond quickly to proliferative cues from the extracellular 
milieu. 
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The ability of overexpressed Myc to facilitate proliferation and inhibit terminal differentiation 
fits well with the fact that tumors of diverse origins contain genetic rearrangements involving 
MYC family genes, such as genomic amplification in neuroblastoma. Indeed, many of the 
genomic alterations in MYC result in increased MYC mRNA levels through increased 
transcription initiation, decreased transcription attenuation, and augmented stability of the 
MYC messenger RNA [40]. Moreover Myc degradation is carried out through the ubiquitin-
mediated proteasome pathway that involves phosphorylation of Thr58 and Ser62 in MB I: 
many tumor-related mutations in Myc result also in significant stabilization of the protein [43, 
44].  
One of the most striking findings of the past years has been the discovery that the enhanced 
expression of Myc proteins contributes to almost every aspect of tumor cell biology [45]. 
Whereas the ability of Myc to drive unrestricted cell proliferation and to inhibit cell 
differentiation had long been recognized, more recent work shows that deregulated expression 
of Myc can drive cell growth and vasculogenesis, reduce cell adhesion, promote metastasis 
and genomic instability. Conversely, the loss of Myc proteins not only inhibits cell 
proliferation and cell growth, but can also accelerate differentiation, increase cell adhesion 
and lead to an excessive response to DNA damage [46]. 
This reflects the surprisingly high number of target genes regulated by Myc, as emerged in 
large-scale analyses of MYC-regulated genes. Indeed, in normal cells, Myc proteins appear to 
integrate environmental signals in order to modulate a wide, and sometimes opposing, group 
of biological functions, including proliferation, growth, apoptosis, energy metabolism, and 
differentiation (see below). 
 
Biological functions of MYC  
 
The vast majority of functional investigations have focused on the c-Myc protein, the most 
studied member of the MYC family. Thus, many of the functions of N-Myc were considered 
common to those of c-Myc. This assumption was based on various experimental evidences: 
• the high level of relatedness between N-Myc and c-Myc protein structure; 
• while c-MYC and MYCN homozygous knockout mice are embryonic lethal, transgenic 
mice in which MYCN replaced c-MYC showed a gross normal development, indicating that 
both proteins have largely overlapping functions [26] [27] [47]; 
• c-Myc and MYCN share >40% of their target genes [48] 
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Nonetheless, since the late 80s, differences between the two members of the MYC family 
appeared to be important and seem more pronounced in recent years of research: actually 
MYCN and c-Myc appear to bind different subsets of genes with different affinities in 
neuroblastoma tumors and in hematopoietic stem cells [49] [50]. 
Furthermore, it is well known the existence of direct negative cross-regulation between 
MYCN and c-Myc [51] [52] [53]. 
Indeed, by analogy with c-Myc, N-Myc has related functions in regulating cell growth and 
proliferation, but in a more specialized context. MYCN is subjected to a strict, rather similar 
temporal and spatial expression pattern, as shown by comparisons of fetal and adult human 
brain cells [54] and by analysis of tissues from different stages of the fetal and the developing 
mouse embryo [55] [4]. These results suggest that MYCN may play an important role during 
mammalian development. The overall expression of the c-MYC gene, in contrast, is virtually 
constant during embryonic development and occurs in all proliferating cells of an organism.  
Altogether, the MYCN and c-MYC genes, in spite of their structural relationship, have 
distinctly different functions. The c-MYC gene plays a more ‘basic’ role, whereas MYCN has 
more specialized functions. 
During murine development MYCN mRNA can be detected as early as day 7.5 in the 
primitive streak [8]. A peak of expression is reached between days 9.5 and 11.5, followed by 
a sharp decrease after day 12.5 [4]. During this time MYCN mRNA is present in many tissues 
including heart, limb buds, and neural tube [55]. MYCN mRNA has also been detected during 
organogenesis in tissues such as hair follicles, lung, liver, and stomach [6]. Within a tissue 
MYCN expression is not homogeneous. For example, in the heart, expression is restricted to 
the myocardium; in the liver it occurs mainly in the peripheral layer; in the neural crest it is 
initially expressed homogeneously, but after colonization of ganglion areas becomes 
restricted to those cells undergoing neuronal differentiation; in the human fetal kidney it is 
observed exclusively in the epithelially differentiating mesenchyme; in the somites it is 
stronger in the posterior than in the anterior half; and in the brain it is observed in the neural 
precursor cells but becomes more restricted after lineage commitment [56]. Thus MYCN 
expression is dynamic not only in space but also in time. At birth MYCN is still expressed in 
the brain, kidney, intestine, lung, and heart but then becomes down-regulated within several 
days or weeks depending on the tissue. In adults, MYCN expression has mainly been detected 
at early stages of B-cell development. However, weak expression may be maintained in the 
adult brain, testis and heart [4]. The lack of MYCN in any tissue where it is normally 
expressed results in developmental defects [56]. 
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Taken together, these results reveal a complex expression pattern of MYCN which is reflected 
in a correspondingly complex promoter with multiple tissue-specific, stage-specific, and 
signal-dependent regulatory elements. As the different expression patterns would lead one to 
expect, the regulatory regions of c-MYC and MYCN are divergent [56]. Among the candidate 
pathways involved in differential regulation of Myc proteins are the Sonic hedgehog pathway 
(Shh) for MYCN activation [57] and the Wnt/beta-catenin pathway for c-MYC activation 
[58]. Sonic hedgehog (Shh) signaling upregulates expression of the proto-oncogene MYCN in 
cultured cerebellar granule neuron precursors. The temporal-spatial expression pattern of 
MYCN, but not other MYC family members, precisely coincides with regions of hedgehog 
proliferative activity in the developing cerebellum [59]. 
These findings are confirmed by studies of human tumor cells. MYCN normally inhibits 
neuronal differentiation by driving germinal cells to maintain their early embryonic short-
duration cell cycles and, therefore, favours self-renewal, genetic instability and cancer [56]. 
Consistent with a critical role of MYCN in the development, overexpression of MYCN within 
a specific developmental window may cause several pediatric tumors of mostly, but not 
exclusively, neuroectodermal origin, including neuroblastoma, rhabdomyosarcoma, 
medulloblastoma, retinoblastoma, astrocytoma, glioblastoma, Wilms’ tumors and small cell 
lung carcinoma [60] [61].  
These data are supported by in vivo experiments: transgenic mice overexpressing MYCN in 
neural crest-derived tissues show frequent development of neuroblastomas [62]. 
Deregulation, for example as the result of amplification in neuroblastoma, could disrupt the 
intrinsic control of MYCN expression and contribute to the euplastic phenotype. It is possible 
that the cellular mechanism which evolved to regulate expression of a single copy of MYCN 
is incapable of efficiently controlling the expression of multiple gene copies. 
It is clear that although neuroblastomas without MYCN amplification show heterogeneity in 
the level of MYCN expression, they never produce as much MYCN as tumors with 
amplification do. In fact, several studies failed to find a correlation between the expression of 
MYCN in non-amplified tumors and an unfavorable outcome, suggesting that a threshold 
level of MYCN expression has to be exceeded for an unfavorable outcome to occur [63].  
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MYC as an activator 
 
MYC encodes a phosphoprotein of apparent molecular weight of 65/67 kDa that is localized 
in the nucleus and binds to DNA [64] [65]. 
When introduced into cells, MYC can activate transcription of synthetic reporter genes 
containing promoter proximal E-boxes in both yeast and mammalian cells [13, 14]. In 
addition, MYCN stimulates natural E-box-containing promoters or sequences derived from 
putative Myc target genes [18, 66-68]. 
Myc-Max heterodimers have relatively weak transactivation activity both endogenously and 
in transient assays [14]. A plethora of microarray studies published recently have shown  that 
Myc proteins activate the majority of target genes by two-fold (generally ranging from 3- to 
10-fold transactivation) [69]. Although Myc is now firmly described as a transcription factor, 
it is certainly feeble compared to other transcription factors. 
In general, transactivation domains of Myc function recruits the basal transcription machinery 
either directly or indirectly. In nearly all cases, TAD function involves interactions with other 
proteins. 
The prevailing model of MYC-mediated transcription postulates, as mentioned above, that 
MYCN increases local histone acetylation at promoters [46]. MYCN binds to histone 
acetyltransferase complexes including TRRAP (transformation/transcription-domain-
associated protein) and either general control of amino-acid-synthesis protein-5 (GCN5) or 
TIP60, which preferentially acetylate histones H3 or H4, respectively [70] [22]. Myc also 
binds to the p300/CBP (CREB-binding protein) acetyltransferases [71].  
The resulted histone acetylation then opens the chromatin and provides docking sites for 
acetyl-histone-binding proteins, including GCN5 and the SWI/SNF chromatin-remodelling 
complex, both of which correlate with increased transcription (Figure 5a) [72] [73]. 
Transcription-factor-mediated recruitment of histone acetyltransferases is now recognized to 
be a major mechanism of transactivation, and many other transcription factors, including TCF 
(T-cell factor), E2F, the tumor suppressor p53 and Gal4, have been subsequently found to use 
this mechanism [74]. The region of chromatin opened through Myc would permit subsequent 
binding and activation by constitutive transcription factors. 
Most of the genes whose expression is induced by Myc are transcribed by RNA polymerase 
II. 
Among others, target genes include the cyclin-dependent kinase CDK4 [75], the Cdc25A 
phosphatase that activates CDKs [76], cyclin D2 [77] [78] and the E2F family [79]. In 
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addition to target genes involved in cell cycle progression, Myc has been found to stimulate 
expression of multiple genes that control cell size and growth, including those encoding 
ribosomal proteins, translation factors, and metabolic enzymes [80]. These findings are 
consistent with the evidence that recruitment of TRRAP and associated acetylation activity is 
also present in vivo at both RNA polymerase III (RNA pol III)-dependent genes and RNA-
pol-I-dependent and ribosomal RNA genes [81] [82] [83] [84].  
Recently Myc has been shown to promote oxidative phosphorylation as well as glycolysis 
through coordinate transcriptional control of the mitochondrial metabolic network [85] [86].  
Regulation of transcription also occurs at the level of transcriptional elongation and not just at 
transcriptional initiation. RNA pol II undergoes a cycle of phosphorylation and 
dephosphorylation during transcription and, with its C-terminal domain (CTD) in a 
hypophosphorylated form, RNA pol II is recruited to promoters. Phosphorylation of the CTD 
occurs during transcription initiation and elongation, whereas the CTD must be 
dephosphorylated to allow RNA pol II to be recycled for another round of transcription. RNA 
pol II has been found to pause on most promoters after transcribing approximately 20–40 
bases. This model fits well with the finding that Myc stimulates the release of paused RNA 
pol II from the promoter and stimulates subsequent transcriptional elongation [87]. This 
correlates with a Myc-dependent increase in RNA pol II phosphorylation: Myc transactivation 
domain (TAD) binds directly CTD kinases (Figure 5b) [88] [89].Myc induction of RNA pol II 
phosphorylation occurs globally throughout the nucleus; it can be detected in the total cellular 
pool of RNA pol II rather than simply at MYC target-gene promoters [90].  
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Figure 5. Mechanisms of MYC-induced transcription. A, Myc recruits histone acetyltransferases, which 
promote localized modification of chromatin through acetylation of nucleosomes. B, Myc recruits basal 
transcription factors and promotes the clearance of promoters through RNA polymerase (pol) II. The Myc 
protein can promote a paused RNA pol to continue transcription of the mRNA by recruiting the P-TEFb 
(positive transcription-elongation factor-b) complex, which phosphorylates the CTD on Ser2 and promotes 
transcriptional elongation [91]. 
 
Moreover, Myc can control protein expression through mRNA translation by promoting the 
methylation of the 5' mRNA guanine or 'cap', which is an essential step for protein-coding 
gene expression. As native levels of Myc regulate the expression of their targets without 
changes in mRNA abundance, this transcription-independent activity has the potential to 
influence all aspects of MYC biology in both normal and tumor cells [90]. 
Along with transcription, the most important nuclear function is DNA replication. The 
genome must be faithfully replicated each cell cycle and the chromosomes must be segregated 
to the daughter cells. Disruption of any step in this process, such as a stalled replication fork 
or DNA damage incurred during S phase, activates a checkpoint that halts the cell cycle until 
the lesion can be repaired. Failure to correct this damage leads to a mutation and/or genomic 
instability. 
Previous studies have provided a link between MYC and genomic instability, but it was 
postulated that this was an indirect consequence of transcriptional activity [92]. A recent 
study describes a direct, non-transcriptional role for MYC in the initiation of DNA 
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replication. Myc was found to bind numerous components of the pre-replicative complex, and 
localize to early sites of DNA replication. These observations suggested that MYC might 
directly control the initiation of S phase and that the MYC effects on genomic instability 
might not depend on the transcriptional induction of S-phase-promoting genes [93]. 
Furthermore much excitement has been generated in the past years about the role of non-
coding, regulatory RNAs. The first oncogenic microRNA polycistron is shown to be regulated 
by MYC [94] [95]. 
Taken together, these findings bring into question the definition of MYC just like a traditional 
transcription factor. It seems to exist an apparent disconnection between MYC’s dramatic 
effects on multiple cellular functions and its molecular characterization as a relatively weak 
transcriptional activator. 
Indeed, the notion that Myc is a general chromatin regulator is nonetheless consistent with 
several recent observations concerning MYC function. First, a series of independent 
expression microarray studies have collectively identified an unexpectedly large group of 
potential genes that are transcriptionally regulated by Myc [96]. Second, recent experiments 
directly assessing genomic binding by Myc suggest binding to thousands of sites throughout 
the genome encompassing approximately 15% of genes as well as intergenic regions [97] [98] 
[99] [69]. Potentially, therefore, Myc regulates a significant proportion of all genes in an 
organism. The number of in vivo binding sites exceeds the number of Myc molecules in 
proliferating cells, which indicates that each site is bound by Myc only temporarily. Most 
probably, therefore, transcriptional regulation by Myc occurs by a 'hit-and-run' mechanism 
whereby the relatively brief binding of Myc triggers longer-lasting changes in the chromatin 
organization at the bound loci [11]. 
Ultimately there are many evidences that MYCN has a robust role in the human genome in 
regulating global cellular euchromatin, including that of intergenic regions. Strikingly, MYCN 
maintains 90% to 95% of total genomic euchromatic marks histone H3 acetylated at lysine 9 
and methylated at lysine 4 modifications in human neuroblastoma, with enhancer-like 
function [100]. In neural stem cells, loss of MYCN is sufficient to cause nuclear condensation, 
most likely due to a global spread of heterochromatin [100]. Myc's recruitment of histone 
acetyltransferases such as GCN5 and TIP60, as well as its regulation of histone acetylation at 
a number of genic loci, suggests that the regulation of euchromatin through histone 
acetylation is involved. Additional evidence suggests that the Myc-regulated chromatin 
program involves also methylation of lysine 4 of histone H3, possibly through the 
demethylase LID [101]. Furthermore Myc may regulate chromatin at a distance such that Myc 
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binding at one location can influence chromatin at another through higher order chromatin 
structure. 
Intriguingly  intergenic binding sites for MYCN are not enriched for E-boxes. Although E-
box–independent binding has been reported and may be fairly widespread [102] such binding 
may be of particular importance for Myc intergenic function. 
A specific global hyperactive chromatin state could be regulated by Myc and locked in place 
during tumorigenesis such as neuroblastoma genesis. 
Furthermore, Myc has been shown to possess another feature outside the context of  E-boxes: 
surprisingly Myc can act as well as a transcriptional repressor at certain target promoters (see 
below) [103]. 
 
 MYC as a repressor 
 
One of the first indicators that MYC might also function as a transcriptional repressor came 
from studies published in the 1980s that suggested that MYC participates in a negative 
feedback loop [104] [105]. After this, genome-wide analyses demonstrate that MYC represses 
at least as many targets as it activates, further emphasizing the role of repression in MYC 
function, including transformation [11].  
Moreover recent findings show that Myc plays a fundamental role as part of the “magic 
quartet” of transcription factors that can reprogram somatic cells to induced pluripotent stem 
(iPS) cells. Ectopic expression of Myc augments the ability of Oct4, Sox2, and Klf4 to induce 
the formation of pluripotent cells from mouse and human fibroblasts, liver cells, and mature B 
cells by a factor of twofold to 10-fold, depending on the cell type [106] [107] [108] [109]. 
Silencing of the somatic cell expression program appears to be an important initial step 
required for the induction of the ES-like expression program, and it is evident a major 
contribution of Myc to this first step [110]. 
The basic mechanism underlying MYC's activation of transcription is well understood, but the 
mechanisms through which MYC negatively regulates or represses transcription are far less 
understood. Once again, several mutant analyses have pointed to the importance of Myc 
BoxII and the BR/HLH/LZ region in both activation and repression by MYC. 
Initially, no simple consensus sequence for transcriptional repression by Myc had emerged. 
This opened the possibility that transcriptional repression is simply an indirect consequence of 
the altered physiological (e.g., transformed) state of a cell that is induced by Myc. Indeed, 
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there is evidence in the literature for such indirect mechanisms of gene repression by Myc 
[111] [112]. 
One argument against the notion that all repression is similarly indirect was the identification 
of mutants of Myc that distinguish transcriptional activation from repression and the detailed 
analysis of the resulting phenotypes [113] [114]. Furthermore DNA elements required for 
Myc-mediated repression has been demonstrated to lie within the promoters of repressed 
target genes, indicating that Myc repression is likely mediated at the transcriptional level 
[103]. 
The repressed genes, like induced genes, fall into multiple functional classes: the first class of 
genes encodes proteins that are selectively expressed in quiescent cells or that directly or 
indirectly inhibit cell proliferation. This group encompasses the cell cycle inhibitors p21Cipl 
[114] [115] [116] [117] [118], p27kipl [119], pl5ink4b [117] [120] [121], pl8ink4c [80], and 
p57kip2 [122], as well as the differentiation-inducing proteins C/EBP-a [123] [124], the 
growth-arrest proteins gas1 and gas2 [113], the growth arrest and DNA damage proteins 
gadd34, gadd45, gadd153 [125] [126], and the Myc-antagonist Mad4 [127]. This long list 
points to a role for Myc-mediated gene repression in the control of cellular differentiation and 
in the response to growth arrest signals. It appears clear that the repression of individual genes 
could significantly contribute to the phenotype of MYC-transformed cells. 
A second class of genes that is often repressed by Myc encodes proteins involved in cell 
adhesion, including a number of integrins: these mRNAs include those encoding cell surface 
proteins such as the class I HLA molecules in melanoma cells, the α3 β1 integrin in 
neuroblastomas, and the LFA-1 (αL β2 integrin) cell adhesion protein in transformed B cells 
as well as [10, 128] [129]. Altered cell adhesion is a hallmark of many Myc-transformed cells 
and has been observed in different cell types [10]. 
Finally, genes involved in metabolic pathway such as thrombospondin and H-ferritin are 
regulate by Myc [130] [131]. Suppression of thrombospondin plays a causative role in the 
induction of angiogenesis by Myc. 
Taken together, these data indicate that MYC has a powerful combination of functions that, 
when deregulated, may drive the limitless replicative potential characteristic of nearly all 
tumors. 
Understanding of MYC repression is significantly advanced with the identification of both the 
specific DNA sequence and the specific MYC-binding proteins that are required for 
repression. 
Recent studies show that not all genes repressed by Myc are silenced by the same mechanism. 
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A number of Myc-repressed targets contain a subclass of initiator elements (INRs; consensus, 
YYCAYYYYY, where Y is a pyrimidine base), which are usually, but not invariably, present 
at TATA-less promoters. INR elements are recognized by TFIID as well as a number of 
regulatory proteins, such as the transcription initiation factor TFII-I, YY-1, and the Myc-
interacting zinc-finger protein 1 (Miz-1). Interestingly, the last three proteins have been 
reported to associate with the BR/HLH/LZ region of Myc [10]. While there has been little 
follow-up on the initial reports involving Myc interaction with TFII-I or YY-1, the association 
of Miz-1 with Myc has been recently confirmed and shown to promote stabilization of Myc 
by inhibiting its ubiquitin-dependent degradation [44]. Miz1 contains 13 zinc fingers and, at 
its amino-terminus, carries a BTB/POZ-domain, which is a protein/protein interaction domain 
found in multiple zinc-finger proteins. Miz1 binds to the 'outside' of the helix–loop–helix 
domain of Myc, but does not interact with Max, Mad or Mnt proteins  [114] [132]. 
Perhaps a stable Myc-Miz1 interaction blocks the ability of Miz1 to initiate transcription at 
INR-containing and other promoters [132]. 
Some Myc-repressed genes, such as gadd45, do not contain INR sequences; rather, repression 
appears to be mediated by a GC-rich region that is potentially recognized by WT1 and p53 
[125]. Another GC-rich binding protein that seems to be important for Myc-mediated 
repression is the basal transcription factor Sp1 (specificity protein 1), a zinc-finger protein 
involved in gene expression in the early development of an organism. Other results show that 
repression by Myc happens through the Smad and the NF-Y binding sites due to direct 
protein/protein interactions between Myc and Smad2 and nuclear factor Y (NFY), 
respectively [133] [134]. 
The data clearly support the notion that several pathways of repression exist. Finally the 
present mechanistic model is that Myc–Max complexes interact with transcriptional activators 
that are bound directly to DNA through enhancer or initiator elements [135] [136]. These 
multi-protein complexes are thought to displace co-activators and recruit co-repressors [137].  
Indeed some genes are repressed by MYC through a mechanism that does not involve the 
Max protein [35] [116]. In fact it was shown that Myc recruits a DNA methyltransferase, 
DNMT3a, to the Myc-Miz1 complex (without Max) on the promoter of p21, indicating that 
Myc-dependent gene repression could at least partly be mediated by methylation of its target 
promoters (Figure 6) [138]. Since Dnmt3a is complexed with histone deacetylases, its 
recruitment by Myc might lead to local histone deacetylation and inhibition of transcription 
[139]. Recruitment of Dnmt3a by Myc is an attractive mechanism for repression, since it 
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might provide an explanation of the aberrant DNA methylation of some tumor suppressor 
genes that is observed in human tumors. 
That Myc can form complexes with proteins outside the Max/Mnt context has been recently 
shown by Orian and colleagues who have found that, in Drosophila, dMyc can directly 
interact with the co-repressor Groucho without Max to control neuronal development [140]. 
Taken together these findings reveal another level of complexity to the mechanisms of Myc 
mediated repression. 
As mentioned above, despite further support for the provocative idea of Myc as a repressor, 
knowledge of the molecular mechanism lagged behind that of MYC as a transactivator. 
Nonetheless, it seems likely that both activation and repression are required for Myc 
biological function. To date still little is known about MYCN-mediated repression. Only few 
genes have been found to be repressed by MYCN: the differentiation-related NDRG1 and -2 
genes (MYCN Downstream-Regulated Genes) via Miz-1-dependent interaction with their 
core promoter [141] [142] and TG2 via SP1-dependent interaction[143]. 
 
Figure 6. Multiple factors employ distinct mechanisms to repress the p21 promoter. Myc exerts their action 
through the proximal promoter region. Myc oncoproteins tend to interfere with positive regulators of p21 
transcription, such as Sp1 and Miz1 [138].  
 
 
Myc And Oncogenesis 
 
 
Deregulated Myc genes  are deeply involved in wide range of human cancer: neuroblastoma, 
osteosarcoma, breast cancer etc. The activation of oncogenic Myc is not due to mutation in 
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the coding sequence that keeps the protein in an active state (ex. HRAS), but is due 
principally to three mechanisms  of activation:  
 Insertional mutagenesis: transduction of a retrovirus coding for a viral Myc (ex. avian 
myelocytomatosis retrovirus MC29[1])or insertion upstream of Myc genes of viruses 
which promoters regulate Myc transcription’[144] (Fig 7a) 
 Chromosomal translocation: after chromosomal translocation Myc became regulated 
by strongly active promoter[145], this is the case of Burkitt lymphoma in which 
chromosomes 14,2 or 22, which harbor the Ig heavy and light chain genes, are 
translocated with chromosome 8, so Myc became regulated by Ig promoter. (Fig 
7a)[146, 147]. 
 Gene amplification: in cancer cells, Myc gene is present in multiple copies or in the 
same chromosome or in extrachromosomal DNA named duble-minutes. (Fig 7a)[148-
150]. 
 
More generally Myc can be deregulated by every kind of mechanisms that converge to Myc 
overexpression (Fig. 7b) and it exerts his role in oncogenesis through modulation of 
transcription of several  target genes involved in all principal  cellular functions. 
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Figure 7. Myc activation mechanisms. 6a Deregulation could occur as a consequence of gross genetic 
abnormalities that affect the MYC locus, including  retroviral promoter or enhancer insertion, chromosomal 
translocation and gene amplification. 6b MYC can be deregulated by many additional mechanisms, including 
activation of hormones or growth factors, their receptors, second messengers or transcriptional effectors that 
converge on MYC expression. Alterations in mechanisms that directly or indirectly stabilize MYC mRNA 
and/or protein can also deregulate expression of this potent oncogene.  Adapted from [11] 
 
 
 
 
The main consequence of Myc deregulation is induction of cell proliferation and block of 
differentiation. In cell whit activated Myc , G1 and G2  are shortened  and cells easily enter in 
S and M  phase; this phenomena is manly due to Myc mediated activation of  cyclin D1, D2 
,E1, A2, as well as CDK4, CDC25A, E2F1 and E2F2. Myc can also mediate  cell cycle 
progression by directly or indirectly repressing transcription of check point genes like 
GADD45, GADD153 and CDK inhibitor genes  for example P21 and P15 [151]. In 
conjunction with cell proliferation deregulation of Myc blocks cell differentiation in many 
different cell types, notably Myc can induce differentiation when commitment to a specific 
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lineage is linked to proliferation[42]. In conclusion Myc over expression  strongly modifies 
the equilibrium between cell proliferation and differentiation  in behalf of proliferation. 
The Myc induced cell proliferation is gained by an appropriate increase of cell metabolism 
and protein synthesis. It’s now well know that Myc up-regulates transcription of genes coding 
for enzymes involved in glucose transport and  metabolism such as Glut1, HK2, PKM2, 
LDHA and PDK1. Furthermore several Myc targets are associated whit mitochondrial 
biogenesis[152]. 
The ability of Myc to regulate the transcription of several components of the protein synthesis 
machinery has been validated in several different cell types. The effect of Myc in stimulating 
protein synthesis is also supported by a direct role of Myc in promoting ribosome biogenesis 
and furthermore  Myc over expression results in  a increased size of nucleoli. Myc also 
promotes ribosome biogenesis at different levels for example by stimulating rRNA 
modification and processing through  direct control of  expression of ribonucleases, rRNA-
modifying enzymes and nucleolar proteins  such as NMP, Nop52, Nop56 and DKC1. 
Moreover Myc protein is localized in the nucleolus and directly regulates rRNA synthesis by 
binding to E-box elements located in the rDNA promoter[153]. 
Another relevant skill of Myc is its  faculty  to induce genomic instability. One of the first  
evidence corroborating this hypothesis was the observation by Mai and co-workers that, after 
Myc deregulation, DHFR locus such as CyclinD2 and  Ribonucleotide Reductase R2 were 
selectively amplified, and continued  Myc expression resulted in rearrangement of the locus, 
along with  additional chromosomal aberrations such as breaks,  and the acquisition of extra 
chromosomal    elements. Furthermore Myc induces reactive ROS, which in turn induce DNA 
breaks. These aberrant phenomena along with Myc induced cell cycling lead to numerical and 
structural alteration of karyotype and the persistence of these lesions during tumor 
progression indicates that they are selected for during tumorigenesis[154, 155]. 
Gene that encodes cytoskeletal and cell adhesion proteins appears to be coordinately 
downregulated by Myc. The collagen genes and several surface protein genes that mediate 
adhesion to extracellular matrix (N- and R- cadherins, integrin β1, fibronectin and fibrillin 1 
and 2 are repressed). The repression of these genes implies morphological changes showed by 
Myc overexpressing cells and the ability to growth in a anchorage-independent way[151]. 
In the late 1990s the ability of Myc  to promote angiogenesis was discovered. Downregulation 
of thrombospondin is vital to angiogenesis and is potentially achieved through MYC 
induction of the miR17–92 microRNA cluster, moreover Myc increases expression and 
release of interleukin 1β that is essential for initiation of angiogenesis.[11] 
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In my PhD thesis I studied n- and  c-Myc  mediated  transcription respectively in 
Neuoroblastoma and Osteosarcoma cell lines and theirs involvement in cancer development. 
 
 
 
Cellular Models 
 
 
Osteosarcoma: an overview. 
Osteosarcoma (OS) is defined as a malignant mesenchymal tumor in which the cancerous 
cells produce bone matrix. Osteosarcoma is the most frequent primary bone sarcoma, 
comprising approximately 15% of all bone tumors and about 0.2% of pediatric tumors 
overall. The age at diagnosis is on the average 16 years for females and 18 years for males 
and with low frequency it also occurs in elderly adults. The most common localizations in 
young adults are areas with rapid bone growth as distal femur, proximal tibia and proximal 
humerus[156]. OS is associated with several genetic predisposition but most OS tumors are 
sporadic without familiar patterns. The diagnosis is usually made by radiographic location of 
tumor lesions and a biopsy for pathologic confirmation. OS has a broad spectrum of 
histological appearances with common characteristics containing highly proliferative 
malignant mesenchymal stem cells and the production of osteoid and/or bone by tumor cells. 
Histologically, OS can be divided into several subtypes. Conventional osteoblastic OS makes 
up about 70%, whereas chondroblastic and fibroblastic OS tumors are the next most common 
at 10% each. Other OS types include anaplastic, telangiectatic, giant cell-rich, and small cell 
OS. Of patients who present no metastatic disease, about 70% will be a long-term survivor. 
The remaining 30% will develop relapse. Pulmonary metastasis is the most common distant 
spread and the main cause of death for OS patients.  
Unlike others sarcoma, no specific translocation or genetic abnormalities have been identified 
in OS, but nearly 70% of OS tumors display a multitude of cytogenetic abnormalities. Besides 
Myc overexpression, another possible cause of genomic instability in OS should be alteration 
of ALT mechanism. ALT is a recombination-based method that prevents telomeres shortening 
which induces cellular senescence and apoptosis. ALT mechanism is altered in about 50% of 
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OS.  
Individuals affected by hereditary retinoblastoma (RB) heterozygous for a germline 
inactivation of RB1 have an approximately 1000 times higher incidence of OS. Genetic 
alterations of RB1 have been found in up to 70% of sporadic OS cases. Loss of heterozygosis 
(LOH) of RB1 locus is present in 60% to 70% of OS tumors. The tumor suppressor gene 
TP53 is located at 17p13, a region frequently identified as abnormal in OS. Alterations in 
TP53 observed in OS tumors consisted of point mutations (20%–30%, mostly missense 
mutations), gross gene rearrangements (10%– 20%), and allelic loss (75%–80%)[157]. 
Among oncogenes the most frequently deregulated are: 
• c-Myc . 12 percent of OS have a Myc  deregulation comprising amplification and 
overexpression. Moreover 42 percent of relapsed patients have a c-Myc 
overexpression. 
•  FOS and JUN.  overexpression of these transcription factor (they act as heterodimers) 
occurs in 61% of OS tumors. 
• MDM2. It is a protein that negatively modulates the activity of TP53. The 12q13 
region containing MDM2 gene is amplified in 10% of OS tumors . 
Recent findings show that the over expression of c-Myc is correlated to chemoresistance to 
methotrexate and has a prognostic value in high grade OS even in patients not treated with 
MTX; this suggests a more wide function of c-Myc in chemoresistance in OS. This 
hypothesis is corroborated by the work of Hattinger et al  [158] where a gain of c-Myc is 
correlated to doxorubicin resistance and again to MTX resistance. 
Actual treatment of OS is composed by multiagents chemotherapy before and after surgical 
resection of primary tumor, without chemotherapy the long-term survival after resection was 
less than 20%. The most used chemotherapy combination is cisplatin (CDDP), doxorubicin 
(DX) and high dose of methotrexate (MTX); this therapy improved the long-term survival till 
to 70% but, still today, about 30% of patients became resistant to chemotherapy agents. 
Possible mechanisms of drug resistance include alterations in: p-glycoprotein expression, 
multidrug resistance protein expression, topoisomerase II, glutathione S-transferases, DNA 
repair, drug metabolism or inactivation, and reduced intracellular influx. Drug resistance can 
be intrinsic (in the absence of treatment) or acquired (after treatment with chemotherapeutic 
agents [157]. 
The most studied gene involved in drugresistance in OS is ABCB1 (P-Glycoprotein/MDR1). 
Several researchers had correlate ABCB1 expression to poorer overall survivor; moreover 
recent works have shown a direct correlation between osteosarcoma drug resistance and 
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ABCB1 overexpression and amplification [158, 159]. ABCB1 is a gene belonging to a wide 
family of genes named ABC Binding Cassette transporter genes. 
 
Neuroblastoma: an overview 
 
Neuroblastoma is the most common extracranial solid tumor in childhood and the most 
frequently diagnosed neoplasm during infancy. It accounts for more than 7% of malignancies 
in patients younger than 15 years and around 15% of all pediatric oncology deaths. The 
overall incidence is about one case in 7,000 live births, and there are about 700 new cases per 
year in the United States. This incidence is fairly uniform throughout the world, at least for 
industrialized nations. The median age at diagnosis for neuroblastoma patients is about 18 
months; so about 40% are diagnosed by 1 year of age, 75% by 4 years of age and 98% by 10 
years of age. [160] 
Neuroblastomas are tumors of the sympathetic nervous system. Due to their neural crest cell 
lineage, neuroblastomas may occur anywhere along the sympathetic ganglia. Most primary 
tumors (65%) occur within the abdomen, with at least half of these arising in the adrenal 
medulla. Other common sites of disease include the neck, chest, and pelvis. The disease is 
remarkable for its broad spectrum of clinical behavior. Although substantial improvement in 
outcome of certain well-defined subsets of patients has been observed during the past few 
decades, the outcome for children with a high-risk clinical phenotype has improved only 
modestly, with long-term survival still less than 40% [161]; [162]. 
From a histological point of view, neuroblastomas can be classified into: 
• immature, consisting of a large population of small neuroblasts, highly undifferentiated, 
with little cytoplasm (neuroblastoma, malignant). 
• partially mature, consisting of ganglion cells (ganglioneuroblastoma, with reduced 
malignancy but capable of to metastasize) 
• fully mature ganglion cells in clusters surrounded by a dense stroma of  Schwann cells 
(ganglioneuroma, benign) 
(Figure 8) [163] [164] 
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Figure 8. Degree of differentiation in neuroblastoma. A, Schwann cells and ganglion cells (indicated by arrows) 
are prominent in stroma-rich neuroblastoma. B, Stroma-poor neuroblastoma consists of densely packed small 
round blue cells with scant cytoplasm. [165] 
 
The differentiation state of the tumor has some prognostic significance, but a more 
sophisticated histopathological classification has been developed to help predict outcome and 
select therapy. 
The generally accepted method is the International Neuroblastoma Staging System (Table 1) 
[166]. 
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Table 1. International Neuroblastoma Staging System [167] 
Stage Definition 
1 
Localized tumor with grossly complete resection with or without 
microscopic residual disease; negative ipsilateral lymph nodes 
2A 
Localized tumor with grossly incomplete resection; negative 
ipsilateral nonadherent lymph nodes 
2B 
Localized tumor with or without grossly complete resection with 
positive ipsilateral nonadherent lymph nodes; negative contralateral 
lymph nodes 
3 
Unresectable unilateral tumor infiltrating across the midline with or 
without regional lymph node involvement, OR  
Localized unilateral tumor with contralateral regional lymph node 
involvement, OR  
Midline tumor with bilateral extension by infiltration (unresectable) 
or by lymph node involvement 
4 
Any primary tumor with dissemination to distant lymph nodes, bone, 
bone marrow, liver, skin or other organs (except as defined for stage 
4S) 
4S 
Localized primary tumor (as defined for stages 1, 2A or 2B) with 
dissemination limited to skin, liver and bone marrow (limited to 
infants <1 year age) 
 
Taken together, the stage of disease, the age of the patient at diagnosis and the site of the 
primary tumor are the most important clinical variables in predicting patient outcome [168] 
[160]. The 2-year disease-free survival of patients with stage 1, 2 and 4S is 80–90%, whereas 
those with stages 3 and 4 have a range of 40–50%. The outcome of infants who are less than 1 
year of age is substantially better than older patients with the same stage of disease, 
particularly those with more advanced stages of disease. Patients with primary tumors in the 
adrenal gland seem to do worse than patients with tumors originating at other sites. 
However, these clinical features are imperfect predictors of tumor behavior. 
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D'Angio and colleagues [169] first described the striking clinical phenotype of stage 4S 
(S=special) disease that occurs in about 5% of cases. These infants have small localized 
primary tumors with metastases in liver, skin, or bone marrow that almost always 
spontaneously regress. Neuroblastoma has the highest rate of spontaneous regression or 
differentiation (i.e. into a benign ganglioneuroma) observed in human cancers: the actual 
frequency of neuroblastomas that are detected clinically and subsequently regress without 
treatment is 5–10% [170]. However the frequency of true asymptomatic neuroblastomas that 
regress spontaneously is probably much higher, and might be equal to the number detected 
clinically. These clinical observations lead to considerable interest in understanding the 
mechanisms underlying spontaneous regression or differentiation, which in turn may lead to 
therapeutic approaches to stimulate these phenomena [170]. 
The etiology of neuroblastoma is still unknown. A subset of patients with neuroblastoma 
shows a predisposition to develop this disease, and this predisposition follows an autosomal 
dominant pattern of inheritance with incomplete penetrance. A family history of 
neuroblastoma is identified in 1–2% of cases [171] [172]. Regression analysis of 
neuroblastoma data was consistent with Knudson's two-mutation hypothesis for the origin of 
childhood cancer [173]. The median age at diagnosis of patients with familial neuroblastoma 
is 9 months, which contrasts with a median age of 18 months for neuroblastoma in the 
general population; these patients often have bilateral adrenal or multifocal primary tumors 
[174] [175]. The concordance for neuroblastoma in twins during infancy indicates that 
hereditary factors might be predominant, whereas the discordance in older twins indicates that 
random mutations or other factors might also be important [176].  
Traditional genetic analyses have identified the short arm of chromosome 16 (16p12-13) as a 
likely predisposition locus, though no causal gene has been identified [177]. 
At the present time, it is unclear if this is the only predisposition locus, or if there are multiple 
loci, but this locus could account for most high-risk families. Neuroblastoma has also been 
seen in several patients with constitutional chromosomal rearrangements, including deletions 
overlapping putative tumor suppressor loci at chromosome bands 1p36 and 11q14-23 [178] 
[179].  
Remarkable disease heterogeneity exists within pedigrees considering affected individuals 
share the same predisposing genetic lesion, suggesting that the pattern of acquired secondary 
genetic alterations ultimately defines the tumor phenotype [170]. 
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Schwab and colleagues first identified a novel MYC-related proto-oncogene, MYCN, that 
was amplified in a panel of neuroblastoma cell lines [2]. MYCN is located on the distal short 
arm of chromosome 2 (2p24): a large region from this site becomes amplified and the MYCN 
locus is copied to form an extrachromosomal circular element or DM (double-minute 
chromatin bodies), with retention of the normal copies of MYCN at 2p24. DMs might 
accumulate by uneven segregation during mitosis; however, in some cases, the amplified 
DNA integrates into a chromosomal locus to form an HSR (homogeneously staining regions) 
(Figure 9) [180] [181] [182] [183]. Other genes might be co-amplified with MYCN in a 
subset of cases, but MYCN is the only gene that is consistently amplified from this locus 
[184]. 
 
Figure 9. MYCN amplification demonstrated by fluorescence in situ hybridization (FISH) using a labeled 
MYCN probe. [165] 
 
Currently it is well known that the most consistently genetic aberration associated with poor 
outcome in neuroblastoma is genomic amplification of MYCN [185] [186]. MYCN 
amplification occurs in roughly 25% of primary tumors and is strongly correlated with 
advanced stage disease and treatment failure (Figure 9) [187] [150]. Its association with poor 
outcome in patients with otherwise favorable disease patterns such as localized tumors or 
INSS stage 4S disease underscores its biological importance [188] [189] [190]. 
Thus, amplification of MYCN remains the most important genetically based independent 
prognostic factor for neuroblastoma and represents an intrinsic biological property of a subset 
of aggressive neuroblastomas: tumors without amplification at diagnosis rarely, if ever, 
develop this abnormality [170]. Figure 10 
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Activation of the MYC genes by amplification is commonly detected in solid human tumors. 
In neuroblastoma MYCN is amplified from 5- to 300-fold per haploid genome, and all the 
copies seem to be transcriptionally active [191] [192]. Therefore tumors with MYCN 
amplification result in an elevated expression of the MYCN protein and this provides 
selective advantage to the cells through various mechanisms that affect the role of MYCN as 
a part of the Myc/Mad/Max transcriptional factor network [193] [191]. 
 
Figure 10. Survival of infants with metastatic neuroblastoma based on MYCN status. A Kaplan–Meier survival 
curve of infants less than 1 year of age with metastatic neuroblastoma. The 3-year event-free survival (EFS) of 
infants whose tumors lacked MYCN amplification was 93%, whereas those with tumors that had MYCN 
amplification had only a 10% EFS [170]. 
 
 
 
ABC Transporter Genes 
 
The ATP-binding cassette (ABC) transporters are the largest family of transmembrane 
transporter protein.  ABC transporters  use the energy from ATP hydrolysis to pump 
compounds across the membrane or to flip molecules from the inner to the outer leaflet of the 
membrane [194-196]. While hydrophobic compounds are the most common substrates, ABC 
transporters are able of transporting metal ions, peptides and sugars. 
ABCs are highly conserved between species, indicating that most of these genes have existed 
since the beginning of eukaryotic evolution. There are 25 ABC genes in E. coli, 29 in S. 
cerevisiae, 56 in C. Elegans, 56 in Drosophila, 51 in Mouse and 48 in Homo Sapiens [197]. 
Introduction 
28 
Human ABC genes are localized on 16 different autosomes and 2 genes reside on the X 
chromosome. Analysis of amino acid sequence alignments of the ATP-binding domains has 
allowed the ABC genes to be classified into subfamilies. There are seven ABC genes 
subfamilies in the human genome, from A to G (Table 2). The most part these subfamilies 
display considerable homology in the trans-membrane (TM) domains and have identical gene 
organization, and similar intron localization.  
 
Table 2. List of human ABC genes, Chromosomal location and Features.[197] 
 
Genes are classified into the ABC superfamily based on the sequence identity of the ATP-
binding domain(s), also known as nucleotide-binding folds (NBFs) [195, 197]. These proteins 
also possess two transmembrane (TM) domains composed of 6–11 membrane-spanning a-
helices. The functional transporter can either be a single protein with two NBFs and two TM 
domains (a full transporter) or be a dimer consisting of two half transporters. Fig. 11.        
Introduction 
29 
 Figure 11.  The structure of three categories of ABC transporter [197] 
 
ABCA subfamily is composed of 12 full transporters that are split into two subgroups [197]. 
The first group (ABCA1–A4, A7, A12, A13) includes seven genes that map to six different 
chromosomes. The second group of ABCA genes (ABCA5–A6, A8–A10) is organized into a 
head-to-tail cluster on chromosome 17q24. This gene cluster is also found in the mouse 
genome.  
The expression pattern of the chromosome 17 genes is restricted with ABCA5 and ABCA10 
expressed in skeletal muscle, ABCA9 in the heart, ABCA8 in the ovary, and ABCA6 in the 
liver. No diseases map to the corresponding region of the mouse and human genomes, and the 
functions are as yet uncharacterized. Probably cluster of ABCA genes in Chr.17 originates by 
gene duplication. ABCA1 controls the extrusion of membrane phospholipids and cholesterol 
toward specific plasmatic acceptors, the apolipoproteins. The ABCA1-dependent homeostatic 
control of the lipid content of the membrane dramatically influences the plasticity and fluidity 
of the membrane. The ABCA4 gene was found to be highly expressed in rod photoreceptors, 
and maps to the region of chromosome 1p21 containing the gene for the Stargardt disease, a 
recessive childhood retinal degeneration syndrome. ABCA4 is believed to mediate transport 
of Vitamin A derivates [197]. 
The ABCA2 gene is highly expressed in oligodendrocytes in the brain; the ABCA7 gene 
highly expressed in the spleen and thymus. The function of these genes, as well as ABCA12 
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and ACBA13, is not known, although it is tempting to speculate that they similarly participate 
in cellular lipid homeostasis in specialized environments. This is supported by the recent 
findings that both ABCA2 and ABCA7 share with ABCA1 a sterol dependent upregulation 
[197].      
The ABCB subfamily is composed of four full transporters and seven half transporters, and 
this is the only human subfamily to have both types of transporters. The ABCB1 
(MDR/PGY1) gene was discovered as a protein overexpressed in certain drug-resistant tumor 
cell lines. Cells that overexpress this protein display MDR and are resistant to or transport a 
wide variety of hydrophobic compounds including colchicine, doxorubicin, adriamycin, 
vinblastine, digoxin, saquinivir, and paclitaxel. ABCB1 is expressed primarily in the liver and 
blood brain barrier, and is thought to be involved in protecting cells from toxic agents. The 
gene is duplicated in mice and animals lacking both genes unfortunately display a very 
limited phenotype and are still viable and fertile. However, they have been very useful models 
to identify and characterize other drug resistance genes. The ABCB4 and B11 proteins are 
both located in the liver and participate in the secretion of phophatidylcholine (PC) and bile 
salts, respectively. Mutations in ABCB4 and ABCB11 are responsible for several forms of 
progressive familial intrahepatic cholestasis (PFIC). Defects in ABCB4 are responsible for 
PFIC3, and are associated with intrahepatic cholestasis of pregnancy. Mutations in the 
ABCB11 gene are found in patients with PFIC2. The ABCB2 and B3 (TAP) genes are half 
transporters that form a heterodimer to transport digested peptides for MHC1 into the ER. 
Rare families with defects in these genes display profound immune suppression, as they lack 
this essential portion of the immune recognition process.  
The remaining ABCB subfamily half transporters are expressed in the lysosome (ABCB9) or 
the mitochondria (ABCB6, B7, B8, and B10). One of the mitochondrial genes (ABCB7) is 
located on the X-chromosome and mutations in this gene are responsible for X-linked 
sideroblastic anemia and ataxia (XLSA/A) phenotype. The human ABCB9 plays a role in 
mitochondrial iron homeostasis and in the biogenesis of cytosolic Fe/S proteins [197].  
The ABCC subfamily contains 12 full transporters that perform functions in ion transport, 
toxin secretion, and signal transduction. The MRPs studied thus far, MRP1–5, are all organic 
anion pumps, but they differ in substrate specificity, tissue distribution, and intracellular 
location, MRPs come in two structural types, one characterized by 17 transmembrane 
segments (MRP1, 2, 3, 6), and one by 12 (MRP4, 5, 7, 8). Cystic fibrosis (CF) is an inherited 
multisystemic disorder characterized by abnormalities in exocrine gland function consequent 
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to loss of function of the CFTR transporter (ABCC7). The CFTR protein is unique among 
ABC proteins in that it is a cAMP-regulated chloride ion channel [198].  
The ABCC8 gene was identified as the locus for familial persistent hyperinsulinemic 
hypoglycemia of infancy, an autosomal recessive disorder characterized by unregulated 
insulin secretion. The remaining ABCC genes are nine MRP-related genes. ABCC1 (MRP1) 
was identified as a multidrug resistance gene and demonstrated to transport glutathione 
conjugates of many toxic compounds. MRP1 is a prototype GS-X pump and a remarkably 
versatile one. It transports a variety of drugs conjugated to GSH, to sulfate or to glucuronate, 
as well as anionic drugs and dyes, but also neutral/basic amphipathic drugs and even 
oxyanions. The oxyanions arsenite and antimonite and the neutral/basic drugs are co-
transported with GSH. Notwithstanding this enormous range of substrates transported, MRP1 
is not indiscriminate [199]. Similar to ABCB1, ABCC1 transports and confers resistance to a 
wide variety of toxic substrates, but is not essential for growth or development. ABCC1 can 
also transport leukotriene C4, a potent chemotactic factor controlling dendritic cell migration 
from peripheral tissues to lymph nodes [197]. MRP2 and MRP1 have about the same size and 
putative membrane topology, and they both transport a similar large range of organic anions. 
However, the tissue distribution of MRP2 is much more restricted than that of MRP1, and 
MRP2 is located in the apical membrane of epithelial cells, whereas MRP1 is basolateral. 
MRP2 has an important function in the biliary excretion of endogenous metabolites, such as 
glucuronosyl-bilirubin, as well as many exogenous compounds. MRP2 is expressed not only 
in the liver but also in the kidney and the intestine of rats and humans. Mutations in the MRP2 
gene cause the Dubin-Johnson syndrome. These patients suffer from an inherited conjugated 
hyperbilirubinemia, which indicates that bilirubin can enter the hepatocytes and is conjugated 
with glucuronate, but is not secreted into bile [197].  
MRP3 is an organic anion transporter, basolateral like MRP1 [200], and prominently present 
in liver, gut, and kidney like MRP2. The strong upregulation of MRP3 in the liver under some 
cholestatic conditions and the ability of MRP3 to transport some bile salts [201] have led to 
speculations that MRP3 might play a role in the enterohepatic recycling of bile salts and in the 
removal of toxic organic anions from the hepatocyte under cholestatic conditions [200]. 
Differently from MRP1 and 2, MRP3 appears unable to transport GSH [200]. This may 
explain why cells transfected with MRP3 gene constructs are not resistant to most of the 
anticancer drugs that are probably cotransported with GSH by MRP1/2. Initial studies on 
MRP3 in a panel of drug-resistant cancer cell lines did not turn up any association between 
MRP3 levels and resistance [202].  
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MRP4 and MRP5 are both organic anion pumps, but they have the interesting ability to 
transport cyclic nucleotides and nucleotide analogs, a class of organic anions apparently not 
transported by MRP1–3 or 6. The transport of nucleotide analogs by MRP4 and 5 can result 
in resistance to clinically used base, nucleoside, and nucleotide analogs, at least in transfected 
cells that highly overproduce MRP4 or 5. The rate of cyclic nucleotide transport by these 
transporters is low and the physiological role of this transport remains to be defined. 
Initial studies on MRP5 showed that this protein is an organic anion pump, able to transport 
acidic organic dyes, S-(2,4-dinitrophenyl)glutathione, GS-DNP, and GSH, and inhibited by 
sulfinpyrazone. However, substantial drug resistance in MRP5-transfected cells was found 
only for 6-mercaptopurine (6MP) and thioguanine (TG), two purine bases that are definitely 
not acidic [199]. Cells with high expression of MRP4 are highly resistant to PMEA and AZT 
and much less resistant to other nucleoside analogs used in antiviral therapy, such as 
lamivudine, ddC, and d4T [203]. MRP4, but not MRP5, confers resistance to short-term 
incubation with high concentrations of MTX. Like MRP4, MRP5 can transport nucleotide 
analogs with a normal pyrimidine ring [199]. The list of substrates transported by MRP4 and 
5 was substantially broadened by vesicular transport studies. Jedlitschky et al. [204] 
discovered that MRP5 can transport cyclic GMP and AMP (cGMP and cAMP), and Hopper 
et al. [205] recently found this for MRP4 as well. The affinity for cGMP is higher than for 
cAMP. The tissue distribution of MRP4 and MRP5 is still not well known. Recent studies 
suggest that MRP4 is more widely expressed than initially thought, with the highest levels in 
kidney and prostate. Analysis of tissue RNA suggests that MRP5 is ubiquitously expressed 
and the highest levels are found in skeletal muscle and brain. Expression of multidrug 
transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and is also able to 
confer significant resistance in vitro to the topoisomerase I poison irinotecan and its active 
metabolite SN-38 [206]. No human disease has been associated with alterations in MRP5, and 
the Mrp5 knock out mouse, has no obvious phenotype. It is possible, however, that the 
overlapping substrate specificities of MRP5 and MRP4 (and possibly MRP8 and 9) may hide 
the physiological function of MRP5.  
Human MRP6 is mainly expressed in liver and kidney, like Mrp6 (MLP-1), its rat homolog, 
but low RNA levels have also been detected in other tissues.  The substrate specificity of 
MRP6 is still unknown. 
The subfamily D contains 4 genes that encode half transporters expressed exclusively in the 
peroxisome. ABCD1– 4, which are also called ALDP, ALDR, PMP70, and PMP69, 
respectively. Interaction between these proteins was demonstrated by co-immunoprecipitation 
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and yeast two-hybrid assays [199]. One of the genes, ABCD1, is responsible for the X-linked 
form of ALD, a disorder characterized by neurodegeneration and adrenal deficiency, typically 
initiating in late childhood. However, there is no correlation between the phenotype of ALD 
and the genotype at the ABCD1 locus. The functions of the other ABCD family genes have 
also not been worked out, but the marked sequence similarity (especially for ALDP-ABCD2) 
suggest that they may exert related functions in fatty acid metabolism. The in vitro 
demonstration of homo- or heterodimerization of the product of ABCD1 with either ALDRP 
or PMP70 suggest that different peroxisomal half transporter heterodimer combinations are 
involved in the import of specific fatty acids or other substrates. ABCD genes are under 
complex regulation at the transcriptional level, and being very tightly linked to cell lipid 
metabolism, it is not surprising that they share with the ABCA and ABCG subclasses the 
sensitivity to the peroxisome proliferator-activated receptor and retinoid X receptor family of 
nuclear receptors [197]. 
The ABCE and ABCF subfamilies are composed of genes that have ATP-binding domains 
that are closely related to those of the other ABC transporters, but these genes do not encode 
any TM domains. The ABCE subfamily contains a single member, the OABP, ABCE1. This 
protein recognizes oligoadenylate produced in response to certain viral infections [197]. The 
ABCE1 gene is the most conserved member of the ABC gene family and is one of the most 
conserved genes in vertebrate and archaeal genomes [207]. This fact alone suggests that the 
gene plays an essential role in biology that is common between archae and eukaryotes. In 
addition, null mutations in the gene are homozygous lethal in every organism that has been 
examined. The ABCE1 protein was originally identified due to an interaction with and 
inhibition of RNase L, a nuclease induced by interferon [208]. However, RNase L is not 
found outside of vertebrates, indicating that ABCE1 has alternate functions. The identification 
of the role of the ABCE1 protein in ribosome biogenesis and in assembly of the pre-initiation 
complex of the ribosome in S. cerevisiae provides a function that is both essential and 
universal to eukaryotes [209]. Recent data show that ABCE1 is essential for in vitro and in 
vivo translation of mammalian proteins. Antisera to ABCE1 blocks in vitro translation of 
mRNA in rabbit reticulocyte lysates but not of poly(U) molecules that can be translated 
independent of initiation factors. As in yeast, ABCE1 interacts with the eukaryotic initiation 
factors eIF5 and eIF2 components of the pre-initiation complex. Inhibition of ABCE1 in 
human cells results in dramatic inhibition of growth, reduction in the amount of large 
polysomes, and incorporation of labeled amino acids into newly synthesized protein. This is 
consistent with the results in yeast and supports a critical role for ABCE1 in the initiation of 
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translation.  A recent work of  Pisarev et Al. demonstrates that ABCE1 plays a pivotal role in 
post termination ribosomal recycling by mediating post termination complex dissotiation 
[210]. The inhibition of ABCE1 could have therapeutic applications. Because the protein is 
essential to most or all eukaryotes, specific inhibitors could be used in the treatment of 
pathogens. For example, inhibitors specific to plasmodia, fungi, and/or protozoan parasites 
could be used to inhibit such organisms as they infect human or other animals. Moreover 
ABCE1 inhibitors efficiently suppress the growth of human tumor cells. The ABCE1 protein 
is unusual in containing a Fe-S cluster binding site. It has long been known that Fe-S clusters 
are assembled in the mitochondria, and this process is essential to the cell. ABCE1 clearly 
represents one essential Fe-S containing protein [207].  
The ABCF proteins  each have a pair of NBF, and the best characterized member is the S. 
cerevisiae GCN20 gene. GCN20 is involved in the activation of the eIF-2 alpha kinase. A 
human homolog, ABCF1 is part of the ribosome complex and may play a similar role [197].  
The human ABCG subfamily contains six half transporters that have an NBF at the N-
terminus and a TM domain at the C-terminus: the reverse of the orientation of all other ABC 
genes. ABCG1 is highly expressed in macrophages and is induced by cholesterol. ABCG4 is 
highly expressed in the brain. It will be interesting to see if these genes have related functions. 
The ABCG5 and ABCG8 genes are located head-to-head on the human chromosome 2p15-
p16, separated by a region of 200 bp. They  are both mutated in families with sitosterolemia, a 
disorder characterized by defective transport of plant and fish sterols and cholesterol. 
Sitosterolemia patients display deficient sterol secretion from the intestine and the liver. This 
genetic evidence indicates that the two half transporters form a functional heterodimer. The 
analysis of cell lines selected for high level resistance to mitoxantrone led to  identification of 
the ABCG2 (ABCP, MXR1, BCRP) as a multidrug transporter. ABCG2 can use 
anthracycline anticancer drugs, as well as topotecan, mitoxantrone, or doxorubicin as 
substrates. The ABCG2 gene is either amplified or rearranged by chromosomal translocations 
in resistant cell lines. Transfection of ABCG2 into cells confers resistance, consistent with its 
functioning as a homodimer. The normal function of ABCG2 is not known; however, it is 
highly expressed in placental trophoblast cells, suggesting that it may pump toxic metabolites 
from the fetal to the maternal blood supply [197]. 
Based on the evidences that the transcription factor c-Myc is correlated to chemoresistance in 
OS and that several ABC transporter are involved in transport of drugs used in OS therapy, 
I tested if c-Myc could regulate transcription of ABC genes in OS cell lines. 
  
 
 
Cyclin G2 
 
A recent paper of Liu and co-workers[143] shows that MYCN interacts with HDAC1 to 
repress TGN2 expression,  we tested the hypothesis that MYCN could interacts also with 
HDAC2 and comparing mRNA expression in BE(2)-C  transfected with scrambled control 
siRNA, MYCN siRNA or HDAC2 siRNA, we identified  Cyclin G2 (CCNG2) gene as a 
possible targets of this regulation.   
Cyclins represent a group of closely related proteins that regulate cyclin dependent kinases  
(CDK) activity at specific stage of cell cycle by binding and forming active complexes with 
specific partner CDKs. Cyclins are thought to confer substrate specificity and regulation 
(activation, inactivation, localization, binding of subunits and others) to Cdk/cyclin 
complexes. Moreover the complexes cyclin-CDK are regulated by specific cyclin-kinase 
inhibitors  (CKI). All the 12 different cyclins found  in mammalian cells contain a 100 amino-
acid homologous region named cyclin box, which  is  the molecular structure marker of 
cyclins[211]. 
Cyclin G is a new member of Cyclin family, which includes Cyclin G1 and Cyclin G2. 
Although the identity of amino acid sequence and nucleotide sequence of cDNA of Cyclin G1 
and Cyclin G2 was 53% and 60% respectively, their biological function and distribution in 
tissue and organ are very different[212, 213]. The molecular structure of cyclin G differs from 
other cyclins. N-terminus lacks a “destruction box” sequence controlling the ubiquitin-
dependent degradation of mitotic cyclins, while contains an epidermal growth factor receptor 
(EGF-R/ ErbB) like autophosphorylation motif in its carboxyl terminus. The structure 
suggested that a role for cyclin G in signal transduction. Cyclin G has not yet been matched 
with a CDK binding partner, and its biologic function is still elusive. Cyclin G is the only 
known cyclin that is transcriptionally activated by the p53 tumor suppressor gene. Cloning 
and sequencing a partial cDNA sequence revealed the cyclin G1 transcript does not encode 
motifs, which resemble known degradation signals. In contrast, the cyclin G2 protein contains 
a prototypic protein destabilizing (PEST) rich sequences, which may be responsible for its 
potential regulated degradation in cell cycle. The cyclin G1 mRNA expression does not 
fluctuate with cell cycle phase, whereas the expression of cyclin G2 mRNA oscillated with 
cell cycle and reached peak in the mid-late S phase. In contrast to cyclin G1, cyclin G2 
mRNA are weakly expressed in skeletal muscles and heart. It is highly expressed in cerebrum, 
thymus, spleen, prostate gland and kidney. Notably cyclin G2 transcripts are abundant in 
  
tissue rich in either terminally differentiated cells or cells reacting to growth inhibitory signals 
and apoptosis. Although Cyclin G1 is a positive regulator and prompts cell proliferation, so 
far, neither the physiological role nor the biochemical function of cyclin G2 has been defined. 
The mRNA expression of Cyclin G1 and cyclin G2 can be induced by DNA-damage drug 
actinomycin-D, which has the p53 dependency for cyclin G1 but the p53 independency for 
Cyclin G2. Negative growth regulators such as TGF-β1 and dexamethasone can induce cyclin 
G2. In the growth inhibition state of B cell, the transcription level of cyclin G2 is up-
regulated. Ectopic expression of VHL oncosoppressor gene into renal cancer cells with VHL 
gene defect can induce cyclin G2 expression. Recently it was also showed that lack of cyclin 
G2 plays an important role in the malignant transformation of papillary carcinoma of the 
thyroid. Moreover cyclin G2 may play an adjuvant role in the transformation of follicular 
adenoma to carcinoma [214]. 
 
 
 
Clusterin 
 
 
Clusterin (CLU) was described as a glycoprotein present in all body fluids and in most human 
tissues. In human was first identified by Jenne and Tshopp in 1989 [215]as a component of 
soluble terminal complement complexes in human serum, then different groups working in 
different research field’s isolated homologues. CLU is expressed at very high levels in many 
different tissues including dermal fibroblast[216], motorneurons [217, 218]and epithelia[219]. 
In other tissues, CLU expression is tightly regulated for instance during cell cycle 
progression[220], atrophy and programmed cell death [221], and in neurodegenerative 
disorders[222]. Today we know that a nuclear form (nCLU), a cytoplasmic Clusterin and a 
secreted form of Clusterin (sCLU) exist. Cytoplasmic Clusterin, which originates from retro 
translocation via the endoplasmic reticulum or Golgi[223], and sCLU are know to cooperate 
with c-Myc in transformation process [224]and to protect cancer cell from death stimuli[225, 
226]. In contrast with this hypothesis recent works show that ectopic expression of Clusterin 
in prostate cancer cells reduces proliferation [227], moreover overexpression of c-Myc in Rat 
fibroblast reduces Clusterin expression[228]. An exemplary case is neuroblastoma cells in 
which Clusterin can mediate resistance to doxorubicin and suppresses in-vitro invasion by 
inhibiting NF-κB[225, 229].   To reconcile these divergent observations, one possible 
  
explanation is that Clusterin roles in tumorigenesis is context and signal dependent. nCLU, 
that probably originates from alternative splicing or an alternative translational start site,  is a 
proapoptotic factor at least in breast and prostate cancer cells [230-232]. 
Clusterin gene is located in chromosome 8p12-21 in close proximity to lipoprotein lipase 
gene locus. It is organized in 9 exons and codes for three transcript isoforms that have a 
unique first exon and share the remaining exons from 2 to 9.   
The three isoforms are named Isoform1 (NM_001831.2), Isoform2 (NM_203339.1) and 
Isoform 11032 . Figure 12.  
 
 
Figure 12. A Schematic representation of Clu gene. Gray blocks are the three unique first exon 1; black blocks 
represent exons from 2 to 9 and black arrows are the transcriptional start sites in-frame in CLU sequence. B 
Schematic representation of CLU mRNA variants.  Adapted from[233] 
 
 
 
 
Isoform 1 is predicted to produce a protein of 501aa with prevalent citoplasmic/nuclear 
localization. 
Isoform 2 is characterized to have an untranslated exon 1, so the first available ATG is in 
exon 2, upstream the ER localization leader sequence. This mRNA is predicted to produce a 
449aa protein that can be secreted. The 276bp long 5’UTR contains an exstensive secondary 
structure and an ORF of 57bp coding for a putative regulatory peptide. 
  
In the Isoform11036 the first exon is located between exon 1 of Isoform1 and 2. The first 
functional in-frame ATG is in the first exon and probably this mRNA code for a 460aa 
protein with a nuclear localization [234]. 
All three transcripts hold an additional in-frame ATG in exon 3 and if translation starts from 
this ATG a shorter form of CLU protein with a supposed nuclear localization is produced 
[235]. 
Recent works show that signalling affecting CLU isoforms are different. For example Wnt 
signalling by TCF1 regulate expression of Isoform1 but not that of Isoform2 [236]; moreover 
in prostate cancer cell line androgens upregulated transcription of Isoform2 and 
downregulates that of Isoform1[237] . The explanation of these phenomena could be the 
existence of different promoters. This was verified only by “in silico” analysis by 
MatInspector software that highlighted two putative promoters P1 and P2 respectively 
upstream to Isoform1 and 2 TSS[238]. Figure 13.  
 
Figure 13. A Schematic representation of Isoforms specific promoter. Adapted from[233] 
 
 
The P1 promoter is the most studied and it characterized by a conventional TATA box, some 
potential AP-1 and AP-2 elements[239] and a domain of 14bp conserved among all analysed 
species named Clusterin Element (CLE). CLE is very similar to Heat-shock Response 
element, it differs only for a base, and this change is not believed to affect binding of heat-
shock factor[240]. A recent study shows that MYCN could indirectly downregulate CLU 
expression through regulation of miR-17-92 expression[241]. 
In this PhD thesis we provide the formal demonstration that MYCN could directly regulate 
Isoform1 expression via direct binding to proximal promoter P1. 
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Transcriptional Activation 
 
Transcriptional Activation Of ABC genes 
 
Expression profile of c-Myc and 17 ABC transporter genes in 34 biopsy of patients with 
OS. 
 
In collaboration with Dr. Serra of Istituto Ortopedici Rizzoli (IOR), biopsies of 34 patients 
and a pool of sane osteoblasts (OBL) were analyzed by Applied Biosystem Custom Micro 
Fluid Card for c-Myc and 17 ACB transporter genes expression’s. In function of c-Myc and 
ABCs expression’s and for each analysed gene, population of 34 patients was divided in two 
sub-populations High expressing (H) and Low expressing (L) choosing as cut-off value the 
medians of expression values of each analysed gene in OBL. The analysed ABC are ABCA2, 
ABCA6, ABCA7, ABCB1 (MDR1), ABCB9, ABCB10, ABCC1 (MRP1), ABCC2 (MRP2), 
ABCC4 (MRP4), ABCC5 (MRP5), ABCC11 (MRP8), ABCC12, ABCE1, ABCF1, ABCF2, 
ABCF3, and ABCG2. Among these genes we founded several which expression correlate to c-
Myc expression (Tab. 1). 
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Correlation Gene 
(Expression vs. 
OBL) 
P value 
(Fisher’s exact test) 
H/H            L/L ABCC1    0.04 
H/H            L/L ABCC4   0.05 
H/H            L/L ABCC11 0.005 
H/H            L/L ABCC2    0.003 
H/H            L/L ABCC5    0.04 
H/H            L/L ABCE1 0.005 
H/H            L/L ABCF1 0.0004 
H/H            L/L ABCF2 0.04 
H/H            L/L ABCF3 0.04 
 
Table 1. ABC genes which expression directly correlate to c-Myc one as identified by Affymetrix Custom Gene 
Card analysis, in 34 biopsies of OS patients.	  
 
 
 
 
C-Myc regulates expression of ABCC1, ABCC4, ABCE1, ABCF1, ABCF2 and ABCF3 in 
Osteosarcoma cell line. 
 
To check the hypothesis if c-Myc could directly regulates the transcription of these ABCs, we 
first performed an in silico analysis of gene promoters and we identified several canonical and 
non canonical E-Boxes in proximity of transcriptional start sites of ABCC1, ABCC4, 
ABCE1, ABCF1, ABCF2 and ABCF3 (Fig.1).  
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Figure 1.	   A	   schematic	   representation	   of	   ABCC1,	   ABCC4,	   ABCE1,	   ABCF1,	   ABCF2	   and	   ABCF3	   promoters	  containing	   canonical	   (red	  arrow)	  and	  non-­‐canonical	   (black	  arrow)	  E-­‐boxes.	  Position	  and	   length	  of	  ChIP	  are	  also	  showed	  (letters).	  
 
 
Then we transfected U2OS and SAOS cell line with c-Myc siRNA and we evaluated 
alteration of the six ABC transporters’ expression by Real Time PCR. As shown in fig. 2 
reduction of c-Myc expression is correlated to a significant reduction of analysed ABC 
transporter expression. 
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Figure 2.	  Transcriptional	  regulation	  by	  C-­‐Myc	  of	  ABCs	  expression.	  (A	  and	  B)	  SAOS	  and	  U2OS	  osteosarcoma	  cell	  lines	  were	  transfected	  with	  scrambled	  control	  siRNA,	  C-­‐Myc	  siRNA	  for	  24	  and	  48	  hours	  respectively,	  followed	   by	   RNA	   extraction	   and	   real-­‐time	   RT-­‐PCR	   analysis	   of	   N-­‐Myc	   and	   ABCs	   expression.	   N-­‐Myc	   and	  ABCs	  gene	  expression	  in	  control	  siRNA-­‐transfected	  cells	  was	  artificially	  set	  as	  1.0.	   
 
 
By Chromatin Immunoprecipitation we confirm that c-Myc directly binds to E-Boxes in gene 
promoters, the results highlight a strong enrichment of ABC promoters’ in c-Myc and Max 
immunoprecipitation Fig 3. 
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Figure 3.	  ChIP	  and	  quantitative	  PCR	  were	  applied	  in	  SAOS	  and	  U2OS	  cell	   lines.	  Fold	  enrichment	  of	  ABCs	  promoter	   regions	   immunoprecipitated	   by	   C-­‐Myc	   and	   Max	   antibodies	   and	   preimmune	   serum	   was	  calculated	   as	   the	   logarithm	   of	   the	   difference	   between	   the	   cycle-­‐threshold	   obtained	   with	   pre-­‐immune	  serum	  and	   the	   cycle-­‐threshold	   obtained	  with	   the	   specific	   antibody.	  Quantitative	   PCR	  was	   performed	   in	  triplicate.	  Results	  were	  the	  average	  of	  three	  independent	  experiments.	  
 
 
Further we cloned the promoters downstream Luciferase gene in pGL3-Basic Vector, then we 
transiently co-transfected U2OS cell line with Luciferase reporter vector and with or without 
c-Myc siRNA, as shown in fig. 4 there is a strong reduction in Luciferase activity in presence 
of c-Myc siRNA. 
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Figure 4.	   Luciferase	  activity	  of	   the	   reporter	   constructs	  of	  ABC	  promoters	   transfected	   in	  U2OS	  cells	  was	  determined	  in	  the	  presence	  (NT)	  and	  absence	  (siRNA	  anti	  c-­‐Myc)	  of	  c-­‐Myc	  expression	  and	  normalized	  to	  that	  of	  Renilla. 
 
C-Myc, ABCC1, ABCC4, ABCE1, ABCF1, ABCF2 and ABCF3 expressions are up-
regulated in MTX, DX and CDDP resistant Osteosarcoma cell lines 
 
In a recent paper Scionti et al [242] has shown an increase of c-Myc expression in SAOS and 
U2OS cell line resistant to high dose methotrexate  (300ng/ml). New data show that also in 
DX and CDDP resistant cell lines c-Myc is overexpressed [158]. From these evidences we 
analysed the expression of the six ABC genes and c-Myc in high dose of MTX, DX and 
CCDP resistant U2OS and SAOS cell lines.  Comparing the expression profile of the analysed 
genes in U2OS vs. relative resistant cell lines, c-Myc and ABCC1, ABCC4, ABCE1, ABCF1, 
ABCF2 and ABCF3 are overexpressed (Fig 5A). Comparison of SAOS vs. relative resistant 
cell lines shows a picture more difficult to interpret, indeed the increase of c-Myc and the 
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analysed ABC genes is not so clear as in U2OS cell lines and in some cases we observe a 
sensible reduction in ABC expressions (Fig. 5B). 
 
Figure 5.	  Expression	  profile	  of	  c-­‐Myc	  and	  ABC	  genes	  in	  Osteosarcoma	  resistant	  cell	  lines.	  (A)	  Expression	  profile	  of	  c-­‐Myc,	  ABCC1,	  ABCC4,	  ABCE1,	  ABCF1,	  ABCF2	  and	  ABCF3	  in	  U2OS	  cell	  line	  was	  compared	  to	  high	  dose	  MTX,	   DX,	   CDDP	   resistant	   U2OS	   cell	   lines.	   After	   total	   RNA	   extraction,	  mRNA	   population	  was	   retro	  transcribed	  and	  analysed	  by	  Real-­‐Time	  PCR.	  (B)	  Comparison	  of	  expression	  profile	  among	  SAOS	  and	  SAOS	  high	  dose	  MTX,	  DX	  and	  CDDP	  resistant	  cell	  lines.	  C-­‐Myc	  and	  ABCs	  gene	  expression	  in	  non-­‐resistant	  U2OS	  and	  SAOS	  were	  artificially	  set	  as	  1.0.	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To clarify the gene expression data obtained from SAOS cell lines, we compared expression 
profile of SAOS and U2OS and we observed that c-Myc and ABCC1, ABCC4, ABCE1, 
ABCF1, ABCF2 and ABCF3 are dramatically overexpressed in SAOS and this could be the 
cause of a reduced variation of analysed gene expression in SAOS vs. SAOS resistant cell 
lines (Fig. 6) 
Figure 6.	  Expression	  profile	  of	  c-­‐Myc	  and	  ABCC1,	  ABCC4,	  ABCE1,	  ABCF1,	  ABCF2	  and	  ABCF3	  genes	  in	  U2OS	  vs.	   SAOS	  cell	   lines.	  After	   total	  RNA	  extraction,	  mRNA	  population	  was	   retro	   transcribed	  and	  analysed	  by	  Real-­‐Time	  PCR.	  C-­‐Myc	  and	  ABCs	  gene	  expression	  in	  U2OS	  were	  artificially	  set	  as	  1.0.	  	   
 
 
High expression of c-Myc, ABCC1, ABCC4 and ABCF1 Osteosarcoma cells correlate to 
more unfavourable outcome. 
 
In collaboration with Dr. Serra of IOR, high and low expression levels of c-Myc, ABCC1, 
ABCC4, ABCE1, ABCF1, ABCF2 and ABCF3 were chosen as criteria to evaluate free event 
survival at six years of 34 OS patients. For each gene, the High and Low expressing sub-
population was analysed by Kaplan-Meier curve. These analyses show that high expression of 
c-Myc, ABCC1, ABCC4 and ABCF1 correlate to a more unfavourable outcome and could be 
used as a prognostic factor to predict conventional therapy failure (Fig.7) 
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Figure 7.	  Prognostic impact of c-Myc, ABCC1, ABCC4 and ABCF1 genes that resulted significantly associated 
with EFS at six years in 34 OS patients, according to Kaplan-Meier curve. 
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Transcriptional Repression 
 
 
Transcriptional Repression Of CCNG2 
 
Cyclin G2 is transcriptionally repressed by HDAC2 and MYCN and reactivated by 
HDAC inhibitors 
 A	  recent	  work	  of	  Liu	  et	  al[143]	  showed	  that	  MYCN	  could	  repress	  transcription	  of	  TG2	  by	  interacting	   with	   Sp1	   	   and	   recruiting	   HDAC1.	   	   In collaboration with group of Dr. Glen 
Marshall (Children's Cancer Institute Australia, Sidney), we decided to check the hypothesis 
that MYCN could	  also	  interact	  with	  HDAC2	  to	  repress	  gene	  expression	  keeping	  in	  mind	  that	  HDAC1	  and	  HDAC2	  have	  an	  high	  grade	  of	  homology.	  Both	   MYCN	   and	   HDAC2	   are	   well	   known	   to	   exert	   biological	   effects	   through	  transcriptional	  regulation.	  We	  performed	  an	  Affymetrix	  microarray	  analysis	  comparing	  mRNA	   expression	   in	   BE(2)-­‐C	   cells	   transfected	   with	   scrambled	   control	   siRNA,	   MYCN	  siRNA-­‐1	  or	  HDAC2	  siRNA-­‐1.	  In	  total,	  18	  genes	  were	  commonly	  upregulated,	  and	  5	  genes	  commonly	   downregulated,	   by	   more	   than	   2	   fold	   by	   both	   N-­‐Myc	   siRNA-­‐1	   and	   HDAC2	  siRNA-­‐1	  (Table	  2).	  Cyclin	  G2	  (CCNG2)	  stood	  out	  in	  this	  microarray	  analysis	  as	  the	  gene	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most	  dramatically	  up-­‐regulated	  by	  HDAC2	  siRNA-­‐1	  (9.7	  fold),	  and	  one	  of	  the	  genes	  most	  dramatically	  activated	  by	  MYCN	  siRNA-­‐1	  (4.8	  fold).	  	   	  
Gene 
description 
GeneBank 
accession  N-Myc siRNA  HDAC2 siRNA 
ZNF36 AA653300  2.564103 2.864103 
HIST1H2BD BC002842 4.967033 2.747253 
SLC35D2 AJ005866 4.638889 2.777778 
TP53INP1 AW341649  5.357377 3.278689 
MYRL2 
 
BF739795  
 
2.066116 
 
4.859504 
 KIAA0699 AI934125  
 
2.145923 
 
3.935622 
 KIAA0265 AF277175  
 
2.320186 
 
3.067285 
 MIAT R54042  
 
2.331 
 
4.694639 
 EST AA195485  
 
2.380952 
 
3.195 
MGC2663 NM_024106 2.487562 3.303 
VDUP1 NM_006472 2.638522 
 
3.372 
ARHGAP21 AB037845 3.175 2.777778 
 G3BP2 AB014560 3.011 
 
2.816901 
 PNRC1 AF279899 3.164557 3.655 
ZNF664 BE965646  3.912 3.846154 
 RBBP2H1A AF087481 4.291845 
 
8.622 
SCG5 
 
NM_003020 4 3.125 
CCNG2 NM_004354 4.854369 9.700 
    
EST  
 
AA524005  
 
0.426 0.240 
AGPAT5 
 
 
AU145356  
 
0.411 0.207 
UHMK1 AI249980 
 
0.382 0.179 
TCF6L1 
 
BE552470  
 
0.347584 
 
0.259645 
 GNPNAT1 
 
BE789346 
 
0.34638 
 
0.237617 
 Table 2. Genes commonly regulated by MYCN-siRNA and HDAC2-siRNA as identified by Affymetrix 
microarray analysis, in Neuroblastoma BE(2)C cells.	  	  	   To	  validate	  the	  microarray	  data,	  we	  performed	  real-­‐time	  RT-­‐PCR	  analysis	  of	  CCNG2	  gene	  expression	   in	   BE(2)-­‐C	   after	   siRNA	   transfection.	   As	   shown	   in	   Figure	   8,	   CCNG2	   gene	  expression	  is	  upregulated	  by	  MYCN	  siRNA,	  HDAC2	  siRNA	  in	  BE(2)-­‐C.	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Figure 8.	   Transcriptional	   regulation	   by	   N-­‐Myc	   and	   HDAC2	   of	   CCNG2	   expression.	   (A	   and	   B)	   BE(2)-­‐C	  neuroblastoma	  cells	  was	  transfected	  with	  scrambled	  control	  siRNA,	  N-­‐Myc	  siRNA	  or	  HDAC2	  siRNA	  for	  48	  hours,	   followed	   by	   RNA	   extraction	   and	   real-­‐time	   RT-­‐PCR	   analysis	   of	   N-­‐Myc	   and	   HDAC2	   expression	  respectively.	  N-­‐Myc	  	  and	  HDAC2	  gene	  expression	  in	  control	  siRNA-­‐transfected	  cells	  was	  artificially	  set	  as	  1.0.	   (C)	   BE(2)-­‐C	   neuroblastoma	   cells	   was	   transfected	   with	   scrambled	   control	   siRNA,	   N-­‐Myc	   siRNA	   or	  HDAC2	   siRNA	   for	   48	   hours,	   followed	   by	   RNA	   extraction	   and	   real-­‐time	   RT-­‐PCR	   analysis	   of	   CCNG2	  expression	   .	  CCNG2	  gene	  expression	  in	  control	  siRNA-­‐transfected	  cells	  was	  artificially	  set	  as	  1.0.	  Symbol	  	  **	  (p<0.01)	  indicated	  statistically	  significant	  differences.	  Error	  bars	  indicated	  standard	  error.	  	  Because	  pan-­‐HDAC	   inhibitors	   repress	   the	  deacetylase	  activity	  of	  HDAC2,	  we	  examined	  whether	   the	   pan-­‐HDAC	   inhibitor,	   trichostatin	   A	   (TSA),	   could	   reactivate	   CCNG2	   gene	  expression.	  As	   shown	   in	  Figure	  9,	   real-­‐time	  RT-­‐PCR	  analysis	   showed	   that	  TSA	  and/or	  tetracycline	   reactivated	   CCNG2	   gene	   expression	   in	   TET21/N	   cell	   line,	   a	   human	  neuroblastoma	   cell	   line	   carrying	   a	  MYCN	   transgene	   under	   the	   control	   of	   a	   TET-­‐OFF	  promoter.	   These	   results	   suggest	   that	   both	   MYCN	   and	   HDAC2	   repress	   CCNG2	   gene	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expression,	  and	  that	  HDAC	  inhibitors	  can	  be	  applied	  to	  reverse	  this	  effect.	  	  
Figure 9.	  Transcriptional	  regulation	  by	  N-­‐Myc	  and	  HDAC2	  of	  CCNG2	  expression.	  TET21/N	  neuroblastoma	  cells	  was	  treated	  with	  tetracycline	  and/or	  TSA	  for	  24	  hours,	  followed	  by	  RNA	  extraction	  and	  real-­‐time	  RT-­‐PCR	  analysis	  of	  CCNG2	  expression.	  CCNG2	  gene	  expression	  in	  control	  was	  artificially	  set	  as	  1.0.	  	  	  	  
N-Myc represses CCNG2 gene transcription by directly binding to HDAC2 at the Sp1 
consensus site of CCNG2 gene core promoter 	  Both	  HDAC2	  [243]	  and	  N-­‐Myc	  [143]	  are	  known	  to	  repress	  gene	  transcription	  by	  binding	  to	  Sp1-­‐binding	  sites	  at	   target	  gene	  promoter.	  As	  both	  N-­‐Myc	  siRNA	  and	  HDAC2	  siRNA	  activated	  CCNG2	  gene	   expression,	  we	   tested	   the	  hypothesis	   that	  N-­‐Myc	  might	   repress	  CCNG2	   gene	   transcription	   by	   recruiting	   HDAC2	   to	   the	   CCNG2	   gene	   promoter.	   Bio-­‐informatics	  analysis	  of	  the	  CCNG2	  gene	  promoter	  (-­‐3000/+3000	  from	  transcription	  start	  site)	   identified	   two	   regions	   enriched	   for	   Sp1	   binding	   sites:	   one	   proximal	   to	   the	  transcription	   start	   site	   and	   a	   second	   one	   located	   about	   1	   kb	   downstream	   from	   the	  transcription	  start	  site	  (Figure	  10).	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Figure 10.	  A	  schematic	  representation	  of	  the	  CCNG2	  promoter	  containing	  the	  Sp1	  binding	  sites	  	  	   The	  CCNG2	  promoter	   region	  was	   scanned	   for	   the	  presence	  of	  N-­‐Myc,	   Sp1	  and	  HDAC2	  binding	   using	   the	   dual	   cross-­‐linking	   ChIP	   assay.	   A	   pre-­‐immune	   serum	  was	   used	   as	   a	  negative	  control	  to	  determine	  the	  baseline	  of	  the	  non-­‐specific	  background.	  As	  shown	  in	  Figure	  11,	  antibodies	  against	  N-­‐Myc,	  HDAC2	  and	  Sp1	  all	  efficiently	  immunoprecipitated	  the	  two	  regions	  of	  the	  CCNG2	  promoter	  carrying	  Sp1	  binding	  sites.	  	  
 
Figure 11.	  Dual	  cross-­‐linking	  ChIP	  and	  quantitative	  PCR	  were	  applied	  in	  BE(2)-­‐C	  cells.	  Fold	  enrichment	  of	  CCNG2	   promoter	   regions	   immunoprecipitated	   by	   anti-­‐Sp1,	   N-­‐Myc,	   HDAC2	   antibodies	   and	   preimmune	  serum	  was	  calculated	  as	   the	   logarithm	  of	   the	  difference	  between	  the	  cycle-­‐threshold	  obtained	  with	  pre-­‐immune	   serum	   and	   the	   cycle-­‐threshold	   obtained	  with	   the	   specific	   antibody.	  Quantitative	   PCR	   targeting	  Amplicon	   A	   and	   Sp1	   binding	   sites	   (Amplicon	   B	   and	   C)	   were	   performed	   in	   triplicate.	   Results	   were	   the	  average	  of	  three	  independent	  experiments.	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To	   confirm	   that	   transcriptional	   suppression	   of	   CCNG2	   was	   mediated	   by	   N-­‐Myc,	   we	  performed	  experiments	  using	  Luciferase	  reporter	  constructs	  carrying	  different	  portions	  of	   the	   CCNG2	   promoter:	   F3(-­‐416/+1188),	   F2	   (+146/+1188),	   F1(+700/+1188),	   F2Δ	  (+146/+825)	   and	   F1Δ	   (+700/+825).	   Reporters	   were	   transiently	   transfected	   into	   the	  TET21/N	   cells.	   Luciferase	   activity	   was	   monitored	   as	   a	   function	   of	   N-­‐Myc	   expression.	  Results	   showed	   that	   deletion	   of	   the	   Sp1	   region	  downstream	  of	   the	   transcription	   start	  site	  abolished	  N-­‐Myc-­‐mediated	  repression	  of	   the	  promoter,	  suggesting	   that	   this	  region	  was	  the	  target	  of	  N-­‐Myc	  and	  HDAC2	  (Figure	  12).	  	  
Figure 12.	  Luciferase	  activity	  of	  the	  reporter	  constructs	  of	  CCNG2	  promoter	  transfected	  in	  TET-­‐21/N	  cells	  was	   determined	   in	   the	   presence	   (-­‐tetracycline)	   and	   absence	   (+tetracycline)	   of	   N-­‐Myc	   expression	   and	  normalized	  to	  that	  of	  Renilla. 	  	   To	  determine	  whether	  N-­‐Myc,	  HDAC2	  and	  Sp1	  are	  part	  of	  the	  same	  repressive	  protein	  complex,	  we	  performed	  co-­‐immunoprecipitation	  (IP)	  assays	  using	  BE(2)-­‐C	  cell	  nuclear	  extracts	  (Figure	  13).	  The	  extracts	  were	   incubated	  with	  a	  specific	  anti-­‐HDAC2	  antibody	  or	   with	   pre-­‐immune	   IgG	   as	   a	   negative	   control.	   The	   IP-­‐complexes	   were	   subsequently	  analyzed	  by	  immunoblot,	  using	  antibodies	  against	  Sp1,	  HDAC2	  and	  N-­‐Myc,	  respectively.	  Results	  showed	  that	  HDAC2	  could	  co-­‐immunoprecipitate	  both	  Sp1	  and	  N-­‐Myc.	  A	  reverse	  experiment	  in	  which	  an	  anti	  N-­‐Myc	  antibody	  was	  employed	  as	  the	  immunoprecipitating	  agent,	   was	   also	   performed.	   Results	   showed	   that	   N-­‐Myc	   could	   efficiently	  coimmunoprecipitate	  both	  HDAC2	  and	  Sp1.	  Taken	  together	  these	  findings	  suggest	  that	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N-­‐Myc	   forms	   a	   protein	   complex	   along	   with	   HDAC2	   and	   Sp1,	   and	   that	   the	   protein	  complex	   represses	   CCGN2	   gene	   transcription	   by	   binding	   the	   Sp1	   containing	   region	  downstream	  of	  the	  transcription	  start	  site.	  	  
Figure 13.	   Protein	   coimmunoprecipitation	   (IP)	   of	   N-­‐Myc	   (left)	   and	   HDAC2	   (right)	   in	   BE(2)-­‐C	   nuclear	  protein	   extracts.	   Products	   obtained	   by	   immunoprecipitating	   with	   either	   anti-­‐N-­‐Myc	   or	   anti-­‐HDAC2	  antibody	  were	  probed	  with	  anti-­‐Sp1,	  anti-­‐HDAC2	  and	  anti-­‐N-­‐Myc	  antibodies	  in	  immunoblot.	  	  	  
Transcriptional repression of CCNG2 contributes to N-Myc and HDAC2-induced cell 
proliferation.  	  Unlike	  most	  other	  cyclins,	  CCNG2	  blocks	  cell	  cycle	  progression	  and	  induces	  cell	  growth	  arrest	  [244]	  [245].	  We	  therefore	  examined	  whether	  transcriptional	  activation	  of	  CCNG2	  contributed	  to	  cell	  growth	  arrest	  induced	  by	  N-­‐Myc	  siRNA	  and	  HDAC2	  siRNA.	  As	  shown	  in	  Figure	  14,	  while	  repression	  of	  CCNG2	  gene	  expression	  alone	  did	  not	  have	  an	  effect	  on	  cell	  proliferation,	  CCNG2	  siRNA	  partly	  blocked	  growth	  arrest	  due	  to	  N-­‐Myc	  siRNA	  and	  to	  HDAC2	  siRNA	  in	  	  BE(2)-­‐C.	  These	  data	  indicate	  that	  transcriptional	  repression	  of	  CCNG2	  contributes	  to	  N-­‐Myc-­‐	  and	  HDAC2-­‐induced	  cell	  proliferation	  in	  neuroblastoma	  cells.	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Figure 14.	   Transcriptional	   repression	   of	   CCNG2	   is	   partly	   responsible	   for	  N-­‐Myc	   and	  HDAC2-­‐modulated	  cell	   proliferation.	   BE(2)-­‐C	   cells	   was	   transfected	   with	   scrambled	   control	   siRNA,	   N-­‐Myc	   siRNA,	   HDAC2	  siRNA,	  CCNG2	  siRNA,	  combination	  of	  CCNG2	  siRNA	  and	  N-­‐Myc	  siRNA,	  or	  combination	  of	  CCNG2	  siRNA	  and	  HDAC2	   siRNA.	   Seventy-­‐two	   hours	   after	   transfection,	   cell	   proliferation	   was	   examined	   by	   BrdU	  incorporation	   ELISA	   and	   expressed	   as	   fold	   changes.	   Symbols	   ***	   (p<0.001)	   indicated	   statistically	  significant	  differences.	  Error	  bars	  indicated	  standard	  error. 	  	  
Transcriptional Repression Of CLU 	  
MYCN mediates negative regulation of CLU expression in Neuroblastoma cell line. 	  	  In	  a	  recent	  work	  Chayka	  and	  colleagues	  [241]	  have	  shown	  that	  MYCN	  induced	  miR-­‐17-­‐92	  microRNA	   cluster	   represses	   Clusterin	  mRNA	   translation.	   In	   collaboration	  with	   Dr.	  Sala	  of	  UCL	  Institute	  of	  Child	  Health	  	  (London,	  GB)	  we	  discovered	  two	  non-­‐canonical	  E-­‐Boxes	  named	  BS1	  and	  BS2	  by	  informatical	  scanning	  of	  Clusterin	  Isoform	  1	  promoter	  (Fig	  15).	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Figure 15.	  A	  schematic	  representation	  of	  Clusterin	  isoform1	  promoter	  containing	  MYCN	  binding	  sites 	  	  To	   check	   the	   hypothesis	   that	   MYCN	   could	   also	   directly	   regulate	   transcription	   of	   CLU	  gene,	  the	  proximal	  promoter	  of	  CLU	  Isoform	  1	  was	  cloned	  upstream	  Luciferase	  gene	  in	  pGL3-­‐Basic	  reporter	  vector.	  By	  gel-­‐shift	  assays,	  conducted	  in	  Sala’s	  Laboratory,	  BS2	  was	  discovered	   to	  be	  bound	  by	  MYCN,	   so	   the	  CLU	   Isoform1	  proximal	  promoter,	   carrying	  a	  point	  mutation	  in	  BS2	  that	  ablate	  MYCN	  binding,	  was	  cloned	  upstream	  Luciferase	  gene	  in	   pGL3-­‐Basic	   reporter	   vector.	   The	   two	   constructs	   were	   transfected	   in	   SHSY5Y	  neuroblastoma	  cell	   line	  with	  or	  without	  expression	  vector	  of	  MYCN.	   	  Luciferase	  assay,	  performed	  in	  Sala’s	  Lab,	  shows	  a	  strong	  reduction	  of	  wild	  type	  CLU	  promoter	  activity	  in	  presence	  of	  high	   level	  of	  MYCN,	   this	  repressive	  effect	  was	   lacking	   in	  BS2	  mutated	  CLU	  promoter.	  (Fig	  16).	  	  
Figure 16.	   Reporter	   constructs	   of	   Clusterin	   isoform	   1	   promoter	   were	   co-­‐transfected	   with	   or	   without	  MYCN	  expression	  vector	  in	  SHSY5Y	  neuroblastoma	  cell	  line.	  Luciferase	  activity	  was	  determined	  after	  24h	  and	  normalized	  to	  that	  of	  Renilla.	  	  
Results 
58  
	  	  	  
MYCN directly binds to CLU promoter in TET21/N neuroblastoma cell line. 	  To	  verify	  the	  binding	  of	  MYCN	  to	  CLU	  promoter	  we	  performed	  a	  ChIP	  in	  TET21/N	  cells	  using	   antibodies	   anti-­‐n-­‐Myc	   and	   anti-­‐Max	   and	  we	   scanned	   by	   Q-­‐PCR	   a	   region	   of	   5Kb	  surrounding	   BS2	   in	   CLU	   promoter.	   The	   MYCN	   and	   Max	   signals	   were	   enriched	   in	  proximity	  of	  BS2	  (Fig	  17).	  
 
Figure 17.	  ChIP	  and	  quantitative	  PCR	  were	  applied	   in	  TET21/N	  neuroblastoma	  cell.	  Fold	  enrichment	  of	  Clusterin	  promoter	  regions	  immunoprecipitated	  by	  C-­‐Myc	  and	  Max	  antibodies	  and	  preimmune	  serum	  was	  calculated	   as	   the	   logarithm	   of	   the	   difference	   between	   the	   cycle-­‐threshold	   obtained	   with	   pre-­‐immune	  serum	  and	   the	   cycle-­‐threshold	   obtained	  with	   the	   specific	   antibody.	  Quantitative	   PCR	  was	   performed	   in	  triplicate.	  Results	  were	  the	  average	  of	  three	  independent	  experiments.	  	  	  Furthermore	   by	   Dual-­‐step	   Chromatin	   IP	   we	   assessed	   the	   presence	   of	   chromatin	  remodeling	  factor	  associated	  to	  transcriptional	  repression	  such	  as	  HDAC1,	  HDAC2,	  BMI1	  (component	   of	   Polycomb	   Repressive	   Complex	   1,	   PRC1)	   and	   SUZ12	   (component	   of	  
Results 
59  
Polycomb	  Repressive	  Complex	  2,	  PRC2).	  As	  shown	  in	  fig	  18,	  the	  same	  regions	  enriched	  in	   MYCN	   and	   Max	   are	   enriched	   for	   HDAC1	   and	   2;	   notably	   regions,	   immediately	  surrounding	   MYCN/Max	   and	   HDACs	   complexes,	   are	   enriched	   in	   SUZ12	  immunoprecipitate	  meaning	  that	  PRC1	  and	  2	  are	  involved	  in	  CLU	  repression.	  	  
Figure 18.	  ChIP	  and	  quantitative	  PCR	  were	  applied	   in	  TET21/N	  neuroblastoma	  cell.	  Fold	  enrichment	  of	  Clusterin	   promoter	   regions	   immunoprecipitated	   by	   HDAC1,	   HDAC2,	   Bmi1	   and	   SUZ12	   antibodies	   and	  preimmune	  serum	  was	  calculated	  as	  the	  logarithm	  of	  the	  difference	  between	  the	  cycle-­‐threshold	  obtained	  with	   pre-­‐immune	   serum	   and	   the	   cycle-­‐threshold	   obtained	  with	   the	   specific	   antibody.	   Quantitative	   PCR	  was	  performed	  in	  triplicate.	  Results	  were	  the	  average	  of	  three	  independent	  experiments.	  	  	   To	   verify	   if	   these	   chromatin-­‐remodeling	   factors	   should	   be	   recruited	   by	   MYCN,	   we	  performed	  a	  Dual-­‐step	  ChIP	   in	  TET21/N	   treated	  with	   tetracycline	   to	   switch-­‐off	  MYCN	  expression.	  As	  shown	  in	  figure	  19,	  in	  absence	  of	  MYCN	  no	  chromatin-­‐remodeling	  factor	  was	   found	  associated	   to	  CLU	  promoter,	   indicating	   that	  probably	   they	  are	   recruited	  by	  MYCN.	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Figure 19.	   ChIP	   and	   quantitative	   PCR	   were	   applied	   in	   TET21/N	   neuroblastoma	   cell	   treated	   with	  tetracycline.	  Fold	  enrichment	  of	  Clusterin	  promoter	  regions	  immunoprecipitated	  by	  C-­‐Myc,	  Max,	  HDAC1,	  HDAC2,	   Bmi1	   and	   SUZ12	   antibodies	   and	   preimmune	   serum	   was	   calculated	   as	   the	   logarithm	   of	   the	  difference	   between	   the	   cycle-­‐threshold	   obtained	   with	   pre-­‐immune	   serum	   and	   the	   cycle-­‐threshold	  obtained	   with	   the	   specific	   antibody.	   Quantitative	   PCR	   was	   performed	   in	   triplicate.	   Results	   were	   the	  average	  of	  three	  independent	  experiments. 	  	  In	   addition	  we	  analyzed	  histone	  modification	  associated	   to	  CLU	  promoter	   in	  presence	  and	  absence	  of	  MYCN	  in	  TET21/N.	  We	  performed	  ChIP	  using	  antibodies	   the	  recognize	  histone	   modification	   involved	   in	   transcriptional	   activation	   such	   as	   acetyl-­‐histone	   H3	  (Ac-­‐H3)	   and	   dimethylated	   lysine	   4	   on	   	   	   histone	   H3	   (dimethyl-­‐H3K4);	   and	   in	  transcriptional	   repression	   such	   as	   trimethylated	   lysine	   9	   and	   27	   on	   histone	   H3	  (trimethyl-­‐	   H3K9	   and	   H3K27	   respectively).	   	   In	   presence	   of	   MYCN,	   we	   observe	   good	  levels	  of	  active	  chromatin	  markers,	  as	  Ac-­‐H3	  and	  dimethyl-­‐H3K4,	  and	  very	  low	  levels	  of	  repressed	   chromatin	   markers	   trimethyl-­‐H3K9	   and	   trimethyl-­‐H3K27.	   This	   pattern	   of	  histone	  modification	   is	   typical	   of	   genes	   repressed	   in	   cancer.	   In	   absence	   of	   MYCN	  we	  found	   a	   strong	   enrichment	   of	   CLU	   promoter	   in	   Ac-­‐H3	   and	   dimethyl-­‐H3K4	  immunoprecipitate	  and	  no	  enrichment	  for	  trimethyl-­‐H3K9	  and	  trimethyl-­‐H3K27.	  Fig	  20	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Figure 20. ChIP	  and	  quantitative	  PCR	  were	  applied	   in	  TET21/N	  neuroblastoma	  cell	   treated	  or	  not	  with	  tetracycline.	   Fold	   enrichment	   of	   Clusterin	   promoter	   regions	   immunoprecipitated	   by	   Ac-­‐H3,	   dimethyl-­‐H3K4,	   trimethyl-­‐H3K9	   and	   trimethyl-­‐	   H3K27	   antibodies	   and	   preimmune	   serum	   was	   calculated	   as	   the	  logarithm	  of	  the	  difference	  between	  the	  cycle-­‐threshold	  obtained	  with	  pre-­‐immune	  serum	  and	  the	  cycle-­‐threshold	  obtained	  with	  the	  specific	  antibody.	  Quantitative	  PCR	  was	  performed	  in	  triplicate.	  Results	  were	  the	  average	  of	  three	  independent	  experiments.	  	  	  
HDACs inhibitor TSA reactivates CLU isoform 1 expression  	  The	   presence	   of	   HDACs	   onto	   Clusterin	   promoter	   suggests	   that	   histone	   deacetylases	  could	   play	   an	   important	   role	   in	   Clusterin	   transcriptional	   repression.	   To	   test	   this	  hypothesis	   and	   to	   confirm	   CLU	   repression	   by	   MYCN,	   we	   exposed	   TET21/N	   cells,	   a	  neuroblastoma	   cell	   line,	   to	   tetracycline	   or	   TSA	   for	   24	   hours.	   As	   shown	   in	   Fig.21	   both	  tetracycline	  and	  TSA	  reactivate	  CLU	  expression.	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Figure 21.	  Transcriptional	  regulation	  by	  N-­‐Myc	  and	  HDACs	  of	  CLU	  expression.	  TET21/N	  neuroblastoma	  cells	  was	  treated	  with	  tetracycline	  or	  TSA	  for	  24	  hours,	  followed	  by	  RNA	  extraction	  and	  real-­‐time	  RT-­‐PCR	  analysis	  of	  CCNG2	  expression.	  CCNG2	  gene	  expression	  in	  control	  was	  artificially	  set	  as	  1.0..	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The Myc oncoproteins are a well-known family of transcription factors belonging to a subset 
of the larger class of proteins containing basic-region/helix–loop–helix/leucin-zipper 
(BR/HLH/LZ) motifs. The Myc family is composed by c-Myc, n-Myc and l-Myc and the 
most studied components of this family are c-Myc and n-Myc because their expression is 
deregulated in many kind of cancer (i.e. Osteosarcoma and Neuroblastoma respectively). 
Trough BR/HLH/LZ motifs they interact with Max (Myc Associated X-factor), and as 
heterodimers they act as transcription factor. The better understood mechanism of Myc-
mediated transcriptional regulation is activation of gene transcription. The Myc-Max complex 
recognizes and binds to a specific sequence CACGTG named E-box. Nonetheless it has been 
shown that beyond “canonical E-boxes” Myc bcan also associate with “non canonical” ones, 
which are degenerate variants of the consensus CACGTG. The most commonly accepted as 
non-canonical E-boxes sequences are: CATGTG and CAGCGC. 
After binding to target sequences, Myc induces transcriptional activation by recruiting 
transcriptional co-activator as the Histone acetylase TIP60 and transformation/transcription 
domain-associated protein TRRAP. Moreover Myc stimulates the release of paused RNA pol 
II from the promoter [87]and stimulates subsequent transcriptional elongation and increases 
RNA pol II phosphorylation: Myc transactivation domain (TAD) binds directly CTD kinases 
[88]. In this thesis we demonstrate that c-Myc/Max complex directly regulates transcription of  
a panel of ABC genes in  OS cell lines. c-Myc amplification or overexpression frequently 
occurs in Osteosarcoma cell. We first analyzed the correlation between c-Myc and 17 ABC 
genes in 34 OS biopsies and we discovered nine (ABCC1, ABCC2, ABCC4, ABCC5, 
ABCC11, ABCE1, ABCF1 ABCF2 and ABCF3) which overexpression correlate to high c-
Myc expression. Among these ABC genes we found that ABCC1, ABCC4, ABCE1, ABCF1, 
ABCF2 and ABCF3 are directly and positively regulated by c-Myc in wild type and in high 
dose (MTX, DX and CCDP) resistant Osteosarcoma cell lines. Furthermore the high 
expression of c-Myc, ABCC1, ABCC4 and ABCF1 have an high prognostic value in the 
analyzed osteosarcoma population, suggesting an high probability of conventional therapy 
failure in patients characterized by this expressional profile. Osteosarcoma is one of most 
common bone tumors in adolescents. Actual therapy is multi drugs treatment before and after 
surgical resection and pharmacological cocktail is composed by Methotrexate, Doxorubicin 
and Cisplatin. Resistance to chemotherapeutic agents is a major obstacle for successful 
treatment of cancer. The failure of the curative treatment of cancer patients often occurs as a 
result of intrinsic or acquired drug resistance of the tumors to chemotherapeutic agents. Our 
results show that Myc directly regulate ABCs transcription also in wild type OS cell lines, 
suggesting that probably Myc overexpression/amplification could predispose cancer cells to 
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drug resistance and that these ABCs could play an important role also in tumor biology. The 
resistance occurs as a cross-resistance to a whole range of drugs with different structures and 
cellular targets. This phenomenon is called multiple drug resistance (MDR). Multidrug 
resistance (MDR) severely limits the effectiveness of chemotherapy in a variety of common 
malignancies and is responsible for the overall poor efficacy of cancer chemotherapy. Often 
deregulation of ABC genes  and c-Myc expression in cancer cells was strongly correlated to 
MDR. Several ABCs have been correlated to resistance to principal drugs used in OS therapy. 
ABCC1, ABCC2, ABCC4, ABCC5 and ABCG2  have been related to Methotrexate 
resistance [246-248]. ABCA3, ABCB1,ABCC1 and ABCG2  are  associated to Doxorubicin 
resistance [249-251], while ABCC2, ABCC4 and ABCF2 were correlated to CCPD resistance 
[252-254]. As we can infer from scientific literature, ABCC1 and ABCC4 frequently recur to 
mediate  resistance to OS drugs. Intriguingly, a recent review of Fletcher et al [255] suggests 
a possible role of ABCC1 and ABCC4 not only in MDR but also in cell mobility, making of 
primary importance the need  to use drugs able to inhibit these trans-membrane proteins. 
My study has also focused on Myc acting as a repressor. First evidences of the relevance of 
Myc-mediated transcriptional repression came from genome-wide analyses which 
demonstrate that Myc represses as many targets as it activates[256]. One of the first 
mechanism defined for the Myc-mediated transcriptional repression was the interaction of 
Myc-Max complex with gene promoters by docking the promoter-bound Sp1 and/or Miz1 
transcription factors, possibly due to interference with their activation functions or by 
recruiting other co-repressors like Dnmt3a [115, 137, 257, 258]. Recently Liu and coworkers 
[143] demonstrated that Myc could repress TG2 transcription by interacting with Sp1 and 
HDAC1 without Max, this was one of the first evidences in mammals that Myc works outside 
of the complex with Max. This finding appears consistent with a recent study in which 
Drosophila dmyc can represses transcription by interacting with Groucho in absence of Max  
[140]. Inline	  with	  these	  studies	  we	  have	  demonstrated	  that	  CCNG2	  expression	  is	  repressed	  by	  an	   Sp1/MYCN/HDAC2	   complex	   in	   neuroblastoma	   cell	   line.	   In	   the	   model	   herein	  proposed,	   MYCN	   interacts	   to	   Sp1	   bound	   to	   CCNG2	   promoter	   and	   recruits	   HDAC2.	   A	  similar	   model	   was	   previously	   proposed	   for	   HDAC1,	   which	   shares	   high	   homology	   to	  HDAC2	  [143].	  These	  particular	  types	  of	  complexes	  may	  appear	  unusual	  considering	  that	  	  Myc	   is	   substantially	   incapable	   to	   work	   as	   transactivator	   without	   Max.	   However	   	   we	  speculate	  that	  an	  excess	  of	  Myc	  in	  the	  cell,	  due	  to	  gene	  amplification	  or	  overexpression,	  may	   compete	   out	   the	   constitutive	  Max	   allow	  a	   “free”	  Myc	   to	   engage	  with	   other	   factor	  	  such	   as	   HDACs.	   In	   the	   case	   of	   CCNG2,	   transcriptional	   repression	   is	   mediated	   	   by	   the	  Sp1/MYCN/HDAC2	   complex.	   Interestingly,	   reactivation	   of	   CCNG2	   by	   TSA	   inhibits	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neuroblastoma	   cell	   growth	   thus	   suggesting	   that	  Myc	  mediated	   repression	   represent	   a	  necessary	   step	   in	  Myc	   induced	  oncogenesis. Cyclin G2 is an atypical member of Cyclin 
family and its expression is associated with terminal differentiation and apoptosis. Moreover 
it blocks cell cycle progression and induces	   cell	   growth	   arrest	   [244,	   245,	   259].	   	   The	  presence	   of	   HDAC2	   in	   this	   repressive	   complex	   is	   quite	   important.	   HDAC2	   promotes	  cancer	  cell	  proliferation	  [260],	  and	  mutation	  of	  HDAC2	  in	  mice	  reduces	  tumor	  incidence	  [261].	  These	  findings	  suggest	  that	  HDACs	  could	  be	  optimal	  targets	  for	  cancer	  therapy. 
Another intriguing hypothesis, which is slowly emerging among Myc experts, is the 
possibility that the complex Myc-Max could mediate transcriptional repression by direct 
binding to peculiar E-boxes. This possibility will greatly complicate the complexity level of 
Myc mediated transcriptional regulation emphasizing the role of context surrounding the E-
box. In an elegant work of Palakurthy and coworkers [262] it was shown that Myc could 
recruit Polycomb Complex 2 after direct binding to DNA and represses transcription of 
RASSF1A gene. Along this line, my study has shown that MYCN represses CLU expression 
by a similar transcriptional repression mechanism. CLU is a multifunctional protein involved 
in many physiological and pathological processes. There are growing evidences that CLU acts 
as an oncosoppressor in Neuroblastoma [229, 241] and others cancer type [216, 224, 227, 
236]. Recently it was shown that MYCN inhibits the expression of CLU in neuroblastoma 
cell lines and primary tumors in part by inducing oncogenic microRNAs belonging to the 
miR17-92 cluster [241]. In collaboration with Dr. Sala of	   UCL	   Institute	   of	   Child	   Health	  	  (London,	   GB),	  we firstly observed a non-canonical MYCN binding site in the 5 flanking 
sequence of Clusterin Isoform1 gene and by reporter assay analyses we measured the  
repressive effect of MYCN on Clusterin promoter. To confirm the MYCN binding to 
Clusterin promoter we performed ChIP and Dual-step ChIP in neuroblastoma cell line and we 
further analyzed the presence of chromatin modifiers (HDACs, PRC1 and PRC2) and histone 
modifications in presence/absence of MYCN using TET21/N cell lines. Data obtained show 
that MYCN/Max complex really binds the Clusterin promoter and the same region is 
immunoprecipitated by HDAC1 and 2 antibodies. Moreover regions immediately flanking 
Clusterin TSS (~+/-1000 bp) are immunoprecipitated by Suz12 antibody indicating that PRC2 
is involved in Clusterin repression. Interestingly in absence of MYCN no chromatin modifier 
was associated with Clusterin promoter meaning that probably MYCN could have a pivotal 
role in CLU repression. Another intriguing finding of this study came from analyses of 
histone modifications of CLU promoter; in absence of MYCN the CLU promoter carries the 
classic histone modifications typical of a transcriptionally active gene (Ac-H3 and dimethyl-
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H3K4), while in presence of MYCN we could observe a strong reduction of activating 
modifications and a slight increase in repressive modifications (trimethyl-H3K9 and –
H3K27). These features resemble the histone modifications found in cancer stem [263] where 
repressed genes are characterized by a “bivalent” signature of histone modifications. Taken 
together these findings suggest that the MYCN/Max complex may directly bind to CLU 
promoter, recruits HDACs thus reducing the level of histone H3 acetylation, and then recruit 
the PRC1 and PRC2 complexes to modify the histone methylation profile. To our knowledge 
these are the first evidences for this kind of MYCN-mediated transcriptional repression. 
Furthermore our results show an increase of Clusterin expression after TSA treatment in 
neuroblastoma cell line, further reinforcing the idea of epigenetic drugs as novel therapeutic 
treatments for Neuroblastoma.	  It	  should	  be	  noted	  that	  HDACs	  are	  present	  in	  all	  genes	  that	  we	  found	  to	  be	  repressed	  by	  MYCN.	  Actually	  more	  than	  a	  dozen	  HDAC	  inhibitors	  are	  currently	  in	  clinical	  trials	  for	  the	  treatment	   of	   malignancies	   of	   various	   organ	   origins,	   and	   the	   HDAC	   inhibitor	   SAHA	   is	  already	   in	   clinical	   use	   for	   the	   treatment	   of	   cutaneous	   T	   cell	   lymphoma.	  Our	   data	   also	  highlight	  the	  potential	  application	  of	  HDAC	  inhibitors	  for	  the	  prevention	  and	  treatment	  of	   MYCN-­‐over-­‐expressing	   neuroblastoma	   because	   HDACs	   inhibitor	   TSA	   significantly	  reactivates	  CCNG2	  and	  CLU	  expression.	  
Final remarks 
 
Overall these studies provide further clarifications on mechanisms of Myc transcriptional 
regulation in cancer and on the contribution of Myc to oncogenesis, particularly in  those 
cancer in which Myc expression is deregulated. Overall our results demonstrate that: 
• c-Myc directly activates transcription of ABCC1, ABCC4, ABCE1, ABCF1, ABCF2 
and ABCF3 in OS cells.  
• N-Myc/Hdac2 complex represses CCNG2 transcription in  neuroblastoma cells. 
• N-Myc/Max complex  represses CLU transcription by direct binding to peculiar E-box 
in neuroblastoma cell line. 
Together these findings provide a more general significance to our observations, suggesting 
that analyzed transcriptional regulations could have a not secondary role in the Myc-mediated 
oncogenesis.  
Taken together our data support the idea that Myc could interact with different partners and it 
could mediate different transcriptional regulation as a function of its cellular level. In normal 
condition, one of the principal functions of Myc/Max complex is to promote the cell cycle 
progression: thus physiologically Myc expression is tightly regulated and restricted during the 
G1/S transition. Furthermore Myc proteins have short half-lives (on the order of 20–30 min), 
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whereas Max, on the other hand, is stable and constitutively expressed (Fig. 1). 
 
 
 
 
 
 
Figure 1.	  Schematic representation of distinct N-Myc complexes, depending on its cellular levels during cell 
cycle, in physiological conditions 
 
When Myc is deregulated and expressed during the whole cell cycle, the Myc/Max 
heterodimers may become overabundant and interfere with other transcriptional factors such 
as Sp1 and Miz1. In this condition the heterodimers could directly bind to lower affinity E-
boxes of activated genes and switch off theirs transcriptional activation by recruiting 
chromatin modifiers (Fig.2) 
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Figure 2.	  Schematic representation of distinct N-Myc complexes, depending on its cellular levels during cell 
cycle, in pathological conditions 
 
Moreover, when significantly overexpressed, for example as the result of amplification in 
neuroblastoma or in other tumours, Myc may establish interactions even outside the Max 
context, such as with Dnmt3a and Hdacs. Fig.3 
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Figure 3.	  Schematic representation of distinct N-Myc complexes, depending on its cellular levels during cell 
cycle, in pathological conditions 
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CELL CULTURES 
 
Human neuroblastoma TET-21N and SK-N-BE(2)C cells were cultured in DMEM containing 
10% heat-inactivated FBS and 50 mg/ml gentamycin. Tet-21N cells were treated with 
tetracycline as described (Lutz et al., 1996; Schuhmacher et al., 2001). 
Human Osteosarcoma SAOS and U2OS cells were cultured in DMEM containing 10% heat-
inactivated FBS and 50 mg/ml gentamycin  
 
RNA EXTRACTION 
 
The step by step protocol is described for cultured cells grown in two 100-mm dishes, 
containing 1-1,5  x  107 cells per dish. Remove the medium and add slowly 1ml of PBS1X. 
Wash and remove. Harvest the cells using trypsin treatment and when the cells detach from 
the culture dish, add 1 volume of fresh medium and transfer the sunspension to a tube. 
Centrifuge for 5 minutes at 1000 rpm, and then remove the supernatant. Add 1-1,5 ml of 
TriReagent (Sigma). Pipet gently up and down and incubate for 5 minutes at room 
temperature. Add 300 µl of chloroform and vortex for 10 seconds. Incubate 5-10 minutes at 
room temperature. Centrifuge fo 5 minutes at 12000rpm at 4°C. Transfer acqueous phase in a 
new tube and add 750 µl of isopropyl alcohol. Mix gently and incubate for 5-10 minutes at 
room temperature. Centrifuge at 12000rpm for 10 minutes at 4°C. Remove the supernatant 
and wash the pellet with 1,5 ml EtOH 75% treated with DEPC and centrifuge at 12000 rpm 
for 5 minutes at 4°C. Remove the supernatant and dry the pellet. Then, resuspend the pellet in 
30-50 µl of DEPC-treated water and heat the sample at 55°C for 10 minutes. 
 
THERMOSCRIPT RT-PCR SYSTEM 
 
The ThermoScript RT-PCR was designed for the sensitive and reproducible detection and 
analysis of RNA molecules in a two-step process. ThermoScript RT, an avian reverse 
transcriptase with reduced RNase H activity, was engineered to have higher thermal stability, 
produces higher yields of cDNA, and produce full-length cDNA. cDNA synthesis was 
performed using total RNA with oligo(dT).  
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In a 0,2-ml tube, combine primer (oligo(dT)), 2µg total RNA and dNTP 10mM mix, adjusting 
volume to 12 µl with DEPC-treated water. Denature RNA and primers by incubating at 65°C 
for 5 min and then place on ice. Vortex the 5X cDNA Synthesis buffer for 5 sec just prior to 
use. Prepare a master reaction mix on ice, with 5X synthesis buffer, 0,1M DTT, RNaseOUT 
(40U/ µl), DEPC-treated water and ThermoScript RT (15units/ µl). Vortex this mix gently. 
Pipet 8 µl of master reaction mix into each reaction tube on ice. Transfer the sample to a 
thermal cycler preheated to the appropriate cDNA synthesis temperature and incubate for 100 
min at 50°C. Terminate the reaction by incubating at 85°C for 5 min. Add 1 µl of RNase H 
and incubate at 37°C for 20min. Add 80 µl of MQ-water for each reaction and store at -20°C 
or use for qPCR immediately. Use only 2-5 µl of the cDNA synthesis reaction for qPCR. 
 
SYBR GREEN qPCR   
 
SYBR GreenER qPCR SuperMix (Invitrogen) for ICycler is a ready to use cocktail 
containing all components, except primers and template, for real-time quantitative PCR 
(qPCR) on ICycler BioRad real time instruments that support normalization with Fluoresceina 
Reference Dye at final concentration of 500nM. It combines a chemically modified “hot-
start” version of TaqDNA polymerase with integrated uracil DNA glycosilase (UDG) 
carryover prevention technology and a novel fluorescent dye to deliver excellent sensitivity in 
the quantification of target sequences, with a linear dose response over a wide range of target 
concentrations. SYBR GreenER qPCR SuperMix for ICycler was supplied at a 2X 
concentration and contains hot-start TaqDNA polymerase, SYBR GrenER fluorescent dye, 1 
µM Fluorescein Reference Dye, MgCl2, dNTPs (with dUTP instead of dTTp), UDG, and 
stabilizers. The SuperMix formulation can quantify fewer than 10 copies of a target gene, has 
a broad dynamic range, and is compatible with melting curve analysis. The TaqDNA 
polymerase provided in the SuperMix has been chemically modified to block polymerase 
activity at ambient temperatures, allowing room-temperature set up and long term storage at 
4°C. Activity is restored after a 10-minutes incubation in PCR cycling, providing an 
automatic hot start for increased sensitivity, specificity and yield. UDG and dUTP in the 
SuperMix prevent the reamplification of carryover PCR products between reactions. dUTP 
ensures that any amplified DNA will contain uracil, while UDG removes uracil residues from 
single or double-stranded DNA. A UDG incubation step before PCR cycling destroys any 
contaminating dU-containing product from previous reactions. UDG is then inactivated by the 
high temperatures during normal PCR cycling, thereby allowing the amplification of genuine 
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target sequences. Fluorescein is included at a final concentration of 500nM to normalize the 
fluorescent signal on instruments that are compatible with this option. Fluorescein can ajust 
for non-PCR-related fluctuations in fluorescence between reactions and provides a stable 
baseline in multiplex reactions. Program real time instrument for PCR reaction as shown 
following: 50°C for 2 minutes hold (UDG incubation), 95°C for 10 minutes hold (UDG 
inactivation and DNA polymerase activation), 40 cycles of: 95°C for 15 seconds and 60°C for 
60 seconds. For multiple reactions, prepare a master mix of common components, add the 
appropriate volume to each tube or plate well, and then the unique reaction components (e.g. 
template, forward and reverse primers at 200nM final concentration). Cap or seal the reaction 
tube/PCR plate, and gently mix. Make sure that all components are at the bottom of the 
tube/plate, centrifuge briefly and place reactions in a pre-heated real-time instrument 
programmed as described above. 
 
ChIP- CHROMATIN IMMUNOPRECIPITATION 
 
The step by step protocol is described for cultured cells grown in two 100-mm dishes, 
containing 1-1,5  x  107 cells per dish. Two 100-mm dishes are used for each 
immunoprecipitation. In the specific case the protocol is intended for human neuroblastoma 
cells growing adhesively. Minor adjustments have to be introduced for other cell types 
especially for those growing in suspension. Based on our experience, one of the most critical 
steps in performing ChIP regards the conditions of chromatin fragmentation, which need to be 
empirically set up for each cell types employed. 
In each plate add 270 µl of formaldehyde from a 37% stock solution and mix immediately. 
Incubate samples on a platform shaker for 10 minutes at room temperature. In each plate add 
500 ml glycine from a 2,5 M stock solution and mix immediately. Incubate on a platform 
shaker for 10 minutes at room temperature. Transfer the plates in ice and remove the medium. 
Harvest the cells with a scraper and then centrifuge at 1500 rpm for 4 minutes in cold 
centrifuge, then keep samples on ice. Remove the supernatant and wash pellet 3 times with 10 
ml ice-cold PBS1X/ 1 mM PMSF. After each washing centrifuge at 1500 rpm for 5 minutes at 
4°C. Remove supernatant and resuspend pellet in 500 µl ice-cold Cell Lysis Buffer. Pipet up 
and down 10-20 times, then incubate on ice for 10 minutes. Centrifuge at 3000 rpm for 5 
minutes at 4°C. Remove supernatant and resuspend pellet in 600 µl ice-cold RIPA buffer. 
Pipet up and down 10-20 times, then incubate on ice for 10 minutes. Sonication of crosslinked 
cells is performed in two distinct steps. First, cells are sonicated with a Branson Sonifier 2 
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times for 15 seconds at 40% setting. Next, cell samples are further sonicated with the Diogene 
Bioruptor for 20 minutes at high potency in a tank filled with ice/water in order to keep cell 
samples at low temperature during sonication. Centrifuge samples at 14000 rpm for 15 
minutes at 4°C. Transfer supernatant to a new tube and pre-clear lysate by incubating it with 
50 µl of Immobilized Protein A [99] for 15 minutes in the cold room at constant rotation. 
Centrifuge samples at 3000 rpm for 5 minutes at 4°C.  Take the supernatant, after having 
saved 50 µl aliquot for preparation of INPUT DNA, and add 5 µg of specific antibody. Rotate 
the sample O/N in the cold room. Add 50 µl of Immobilized Protein A [99] and incubate by 
constant rotation for 30 minutes at room temperature. Centrifuge the sample at 4000 rpm for 5 
minutes at room temperature. Remove the supernatant and proceed to wash the beads. For 
each wash, incubate the sample by constant rotation fro 3 minutes at room temperature and 
the centrifuge at 4000 rpm for 2 minutes at room temperature. Wash 4 times with 1 ml Ripa 
Buffer. Wash 4 times with 1 ml Washing Buffer. Wash 2 times with 1 ml TE buffer. Remove 
the supernatant and add 200 µl TE buffer to the beads. Add 10 µg RNAse A and incubate at 
37°C for 30 minutes. Add 50 µl Proteinase K Buffer 5X and 6 µl Proteinase K (19 mg/ml). 
Then, incubate at 65°C in a shaker at 950 rpm for 6 hrs. Centrifuge at 14000 rpm for 10 
minutes at 4°C, then transfer the supernatant (250 µl) to a new tube.  
Extract once with phenol/chlorophorm/isoamylalcohol. Recover the aqueous phase (200 µl) 
and transfer to a new tube. Add 100 µl TE buffer to the remaining phenol/chlorophorm 
fraction and re-extract DNA. Recover the aqueous phase and add it to the previous one. 
Extract once with chlorophorm/iso-amyl-alcohol. Recover the aqueous phase (200 µl) and 
transfer to a new tube. Add 1 µl glycogen (Glycogen is 20 mg/ ml stock solution), 10 µg 
Salmon Sperm, 1/10 volumes Na-acetate 3M pH 5.2, and 2.5 volumes of cold ethanol100% 
Vortex and precipitate at -80°C for 40 minutes. Centrifuge at 14000 rpm for 30 minutes at 
4°C. Remove the supernatant and wash pellet with 200 µl EtOH 70%. Resuspend IP-DNA 
and INPUT samples in 50-100 µl 10 mM TrisHCl pH 8.  Use 2-4 µl of IP-DNA for Real 
Time PCR analysis. 
Cell Lysis Buffer:                                     RIPA Buffer                                      Washing 
buffer 
5 mM PIPES pH 8                                      150mM NaCl                              100mM TrisHCl 
pH 8 
85 mM KCl                                                 1% NP40                                    500mM LiCl  
0,5% NP40                                                  0,5% NaDoc                               1% NP40 
1 mM PMSF                                                0,1% SDS                                   1% NaDoc 
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Protease inhibitor cocktail  [264]            50 mM TrisHCl pH 8 
                                                                     1 mM PMSF 
                                                                     Protese inhibitor cocktail [264] 
 
DUAL-STEP CHROMATIN IMMUNOPRECIPITATION 
 
The step by step protocol is described for cultured cells grown in two 100-mm dishes, 
containing 1-1,5  x  107 cells per dish. Two 100-mm dishes are used for each 
immunoprecipitation. In the specific case the protocol is intended for human neuroblastoma 
cells growing adhesively. Minor adjustments have to be introduced for other cell types 
especially for those growing in suspension. Based on our experience, one of the most critical 
steps in performing ChIP regards the conditions of chromatin fragmentation, which need to be 
empirically set up for each cell types employed. 
Remove medium and add 2 ml PBS 1X/ 1 mM PMSF to each plate  and scrape cells at room 
temperature. Pool together the cells from two plates and centrifuge at 1500 rpm for 5 minutes 
at room temperature. Wash cell pellet with 20 ml PBS1X/ 1 mM PMSF at  room temperature 
and centrifuge at 1500 rpm for 5 minutes. Repeat this step 3 times. Resuspend pellet in 20 ml 
PBS1X/ 1 mM PMSF.  Add disuccinimidyl glutarate (DSG) to a final concentration of 2mM 
and mix immediately. DSG is prepared as a 0.5 M stock solution in DMSO. (Note1) Incubate 
for 45 minutes at room temperature on a rotating wheel at medium speed (8-10 rpm). At the 
end of fixation, centrifuge the sample at 1500 rpm for 10 minutes at room temperature. Wash 
cell pellet with 20 ml PBS1X/ 1 mM PMSF at room temperature and centrifuge at 1500 rpm 
for 5 minutes. Repeat this step 3 times. Resuspend pellet in 20 ml PBS1X/ 1 mM PMSF. Add 
540 µl formaldehyde from a 37% stock solution and mix immediately. Incubate samples on a 
rotating wheel for 15 minutes at room temperature. Add 1 ml glycine from a 2,5 M stock 
solution and mix immediately. Incubate on a rotating wheel for 10 minutes at room 
temperature. Centrifuge samples at 1500 rpm for 4 minutes in cold centrifuge, then keep  
samples on ice. Remove the supernatant and wash pellet 3 times with 10 ml ice-cold PBS1X/ 
1 mM PMSF. After each washing centrifuge at 1500 rpm for 5 minutes at 4°C. Remove 
supernatant and resuspend pellet in 500 µl ice-cold Cell Lysis Buffer. Pipet up and down 10-
20 times, then incubate on ice for 10 minutes. Centrifuge at 3000 rpm for 5 minutes at 4°C. 
Remove supernatant and resuspend pellet in 600 µl ice-cold RIPA buffer. Pipet up and down 
10-20 times, then incubate on ice for 10 minutes. Sonication of crosslinked cells is performed 
in two distinct steps. First, cells are sonicated with a Branson Sonifier 2 times for 30 seconds 
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at 40% setting. Next, cell samples are further sonicated with the Diogene Bioruptor for 20 
minutes at high potency in a tank filled with ice/water in order to keep cell samples at low 
temperature during sonication. (Note 3)  Centrifuge samples at 14000 rpm for 15 minutes at 
4°C. Transfer supernatant to a new tube and preclear lysate by incubating it with 50 µl of 
Immobilized Protein A [99] for 15 minutes in the cold room at constant rotation. Centrifuge 
samples at 3000 rpm for 5 minutes at 4°C.  Take the supernatant, after having saved 50 µl 
aliquot for preparation of INPUT DNA, and add 5 µg of specific antibody. Rotate the sample 
O/N in the cold room. Add 50 µl of Immobilized Protein A [99] and incubate by constant 
rotation for 30 minutes at room temperature. Centrifuge the sample at 4000 rpm for 5 minutes 
at room temperature. Remove the supernatant and proceed to wash the beads. For each wash, 
incubate the sample by constant rotation fro 3 minutes at room temperature and the centrifuge 
at 4000 rpm for 2 minutes at room temperature. Wash 4 times with 1 ml Ripa Buffer. Wash 4 
times with 1 ml Washing Buffer. Wash 2 times with 1 ml TE buffer. Remove the supernatant 
and add 200 µl TE buffer to the beads. Add 10 µg RNAse A and incubate at 37°C for 30 
minutes. Add 50 µl Proteinase K Buffer 5X and 6 µl Proteinase K (19 mg/ml). Then, incubate 
at 65°C in a shaker at 950 rpm for 6 hrs. Centrifuge at 14000 rpm for 10 minutes at 4°C, then 
transfer the supernatant (250 µl) to a new tube.  
Extract once with phenol/chlorophorm/isoamylalcohol. Recover the aqueous phase (200 µl) 
and transfer to a new tube. Add 100 µl TE buffer to the remaining phenol/chlorophorm 
fraction and re-extract DNA. Recover the aqueous phase and add it to the previous one. 
Extract once with chlorophorm/iso-amyl-alcohol. Recover the aqueous phase (200 µl) and 
transfer to a new tube. Add 1 µl glycogen (Glycogen is 20 mg/ ml stock solution), 10 µg 
Salmon Sperm, 1/10 volumes Na-acetate 3M pH 5.2, and 2.5 volumes of cold ethanol100% 
Vortex and precipitate at -80°C for 40 minutes. Centrifuge at 14000 rpm for 30 minutes at 
4°C. Remove the supernatant and wash pellet with 200 µl EtOH 70%. Resuspend IP-DNA 
and INPUT samples in 50-100 µl 10 mM TrisHCl pH 8 Use 2-4 µl of IP-DNA for Real Time 
PCR analysis. 
 
Notes 
1).We have tested several crosslinking agents including DSG (disuccinimdyl glutarate), EGS 
[ethylene glycol bis(succinimidylsuccinate], DMA (dimethyl adipimidate) and DSS 
(disuccinidimyl suberate). In our conditions, DSG was the one that worked best, although we 
also obtained good results with EGS. 
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2) Sometimes, insoluble aggregates form when DSG is added to cells resuspended in PBS 1X 
. However, this seems not to preclude the efficiency of the crosslinking reaction.  
3) Through this procedure we could efficiently fragment chromatin in a range between 500 
and 200 bp. As stated above, this is a critical step that must be empirically set up for each cell 
line tested. For example, HL-60 cells that grow in suspension, are sonicated with a Branson 
Sonifier 4 times for 30 seconds at 40% setting and subsequently with the Biogene Bioruptor 
at a full power for 30 minutes. This procedure allows fragmentation of HL-60 chromatin to a 
size range of 1000-500 bp. 
 
Cell Lysis Buffer:                                     RIPA Buffer                                      Washing 
buffer 
5 mM PIPES pH 8                                      150mM NaCl                              100mM TrisHCl 
pH 8 
85 mM KCl                                                 1% NP40                                    500mM LiCl  
0,5% NP40                                                  0,5% NaDoc                               1% NP40 
1 mM PMSF                                                0,1% SDS                                   1% NaDoc 
Protease inhibitor cocktail  [264]            50 mM TrisHCl pH 8 
                                                                     1 mM PMSF 
                                                                     Protese inhibitor cocktail [264] 
LUCIFERASE ASSAY 
 
The Dual-Luciferase® Reporter (DLR.) Assay System (Promega) provides an efficient means 
of performing dual-reporter assays. In the DLR. Assay, the activities of firefly (Photinus 
pyralis) and Renilla (Renilla reniformis, also known as sea pansy) luciferases are measured 
sequentially from a single sample. The firefly luciferase reporter is measured first by adding 
Luciferase Assay Reagent II (LAR II) to generate a stabilized luminescent signal. After 
quantifying the firefly luminescence, this reaction is quenched, and the Renilla luciferase 
reaction is simultaneously initiated by adding Stop & Glo® Reagent to the same tube. The 
Stop & Glo® Reagent also produces a stabilized signal from the Renilla luciferase, which 
decays slowly over the course of the measurement. In the DLR. Assay System, both reporters 
yield linear assays with subattomole sensitivities and no endogenous activity of either reporter 
in the experimental host cells. Furthermore, the integrated format of the DLR. Assay provides 
rapid quantitation of both reporters either in transfected cells or in cell-free 
transcription/translation reactions. 
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Note: The LAR II, Stop & Glo® Reagent and samples should be at ambient temperature prior 
to performing the Dual-Luciferase® Assay. Prior to beginning this protocol, verify that the 
LAR II and the Stop & Glo® Reagent have been warmed to room temperature. 
 
The assays for firefly luciferase activity and Renilla luciferase activity are performed 
sequentially using one reaction tube. The following protocol is designed for use with a 
manual luminometer or a luminometer fitted with one reagent injector.  
Predispense 100µl of LAR II into the appropriate number of luminometer tubes to complete 
the desired number of DLR. Assays. Program the luminometer to perform a 2-second 
premeasurement delay, followed by a 10-second measurement period for each reporter assay. 
Carefully transfer up to 20µl of cell lysate into the luminometer tube containing LAR II; mix 
by pipetting 2 or 3 times. Do not vortex. Place the tube in the luminometer and initiate 
reading. 
 
Note: We do not recommend vortexing the solution at Step 3. Vortexing may coat the sides of 
the tube with a microfilm of luminescent solution, which can escape mixing with the 
subsequently added volume of Stop & Glo® Reagent. This is of particular concern if Stop & 
Glo® Reagent is delivered into the tube by automatic injection. 
If using a manual luminometer, remove the sample tube from the luminometer, add 100µl of 
Stop & Glo® Reagent and vortex briefly to mix. Replace the sample in the luminometer, and 
initiate reading.Discard the reaction tube, and proceed to the next DLR. Assay. 
 
CO-IMMUNOPRECIPITATION ASSAYS 
 
The interaction between different proteins is assessed by immunoprecipitation and Western 
blotting. Cells are washed two times in PBS 1X+ PMSF (0,1%) and lysed in the following 
buffer for isolation of nuclei: Hepes 10mM, NaCl 50 mM, EDTA 1mM, DTT 1mM, 
NaPirophosphate 1 mM, NaOrtovanadate 1 mM, Nafluorophosphate 1 mM, PMSF 1 mM, 
protease inhibitor (Complete, ROCHE). Nuclei are lysed in  Tris-Cl pH 7,5 50 mM, NaCl 150 
Mm, EDTA 10 mM, DTT 1 mM, protease inhibitors. Nuclear lysate (1 mg) is 
immunoprecipitated with  antibody to HDAC (Upstate), N-Myc, SP1 (Upstate) overnight at 
4°C. The day after, specific immunoprecipitated material is incubated with 40µl of slurry-
beads protein A, allowing the link between our specific antibody and protein A. The beads 
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with immunocomplexes are washed five times with  nuclear lysis buffer + NP40 0,25% and 
boiled in Laemmli sample buffer for  5 min at 100°C.  Eluted proteins are separated by SDS-
PAGE and analyzed by Western blot. 
 
IMMUNOBLOTTING ANALYSIS 
 
Western blots were performed according to Invitrogen procedures for NuPAGE Novex 4-12% 
Bis-Tris Gel Electrophoresis system, using 100 µg of whole-cell extracts.  
 
GENE SILENCING, TRANSFECTION AND CELLULAR ASSAYS  
 
Lipofectamine RNAiMAX reagent (Invitrogen) was used to deliver short interfering RNAs 
(siRNA) according to the manufacturer’s instructions.  
BrdU incorporation was measured using a Cell Proliferation ELISA (Roche Diagnostics). 
Transduced SK-N-BE cells were plated in 96-well plates at a cell density of 15,000 cells per 
well with 100 ml DMEM medium and cultured for 48h before addition of BrdU for 2h 
followed by assay according to the manufacturer’s protocol. 
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